Therapeutic Significance of 1,4-Dihydropyridine Compounds as Potential Anticancer Agents

*Tangali Ramanaik Ravikumar Naik*

## **Abstract**

A series of 1,4-dihydropyridines have been prepared from a three-component one-pot condensation reaction of β-diketonates, an aromatic aldehyde, and ammonium acetate under microwave irradiation. The reaction is performed using crystalline nano-ZnO in ethanol under microwave irradiation (CEM discover). A wide range of functional groups was tolerated in the developed protocol. The present methodology offers several advantages such as simple procedure, greener condition, excellent yields and short reaction time. The synthesized compounds were evaluated for DNA photocleavage, SAR analysis and molecular docking studies. The compound (**4b, 4c, 4 h, 4i, 4n** and **4o**) showed potent DNA cleavage activities compared to other derivatives. The molecular interactions of the active compounds within the binding site of B-DNA were studied through molecular docking simulations; the compound (**4b, 4c, 4 h, 4i, 4n** and **4o**) showed good docking interaction with minimum binding energies. All synthetic compounds were characterized by different spectroscopic techniques.

**Keywords:** 1,4-Dihydropyridines, DNA photocleavage, molecular docking, SAR analysis, ZnO nanoparticle

## **1. Introduction**

Facile and efficient synthesis of biological active molecules is one of the main objectives of organic and medicinal chemistry. In recent years, multicomponent reactions have become one of the important tools in the synthesis of structurally diverse chemical libraries of drug-like polyfunctional organic molecules [1–4]. Furthermore, MCRs offer the advantage of simplicity and synthetic efficiency over conventional chemical reactions in several aspects. MCRs allow the construction of combinatorial libraries of complex organic molecules for an efficient lead structure identification and optimization in drug discovery [5–10].

In continuation of our ongoing research work on microwave assisted synthesis of nano materials [11, 12] we have found that, nano-crystalline metal oxides have attracted considerable attention of synthetic and medicinal chemists because of their high catalytic activity and reusability [13–25]. Zinc oxide is an inexpensive, moisture stable, reusable, commercially available and is non-toxic, insoluble in polar as well as non-polar solvents [26–31]. A wide range of organic reactions that include Beckmann rearrangements [32], N-benzylation [33], acylation [34], dehydration of oximes [35], nucleophilic ring opening reactions of epoxides [36],

synthesis of cyclic urea [37], N-formylation of amines [38]. In particular crystalline nano-ZnO oxide exhibit better catalytic activity compared to their bulk sized counterparts [29, 39–42].

In recent years, much attention has been directed toward the synthesis of dihydropyridine compounds owing to their tremendous application in various research fields including biological science and medicinal chemistry [43, 44]. Many DHPs are already commercial products such as: amlodipine, felodipine, isradipine, lacidipine, nicardipine, nitrendipine, nifedipine and nimodipine B, of which nitrendipine and nemadipine B exhibit potent calcium channel blocking activities [45–49] (**Figure 1**) and have emerged as one of the most important classes of drugs for the treatment of cardiovascular diseases [50, 51]. Moreover dihydropyridine derivatives possess a variety of biological activities like, geroprotective, hepatoprotective, anti-atherosclerotic, antitumor, and antidiabetic activities [46, 52, 53]. Widespread studies have uncovered that dihydropyridine unit containing compounds exhibit various medicinal functions such as neuroprotectant, platelet anti-aggregatory activity, cerebral anti ischemic activity in the treatment of Alzheimer's disease, chemosensitizer in tumor therapy [54–56]. Drug-resistance modifiers [57], antioxidants [58] and a drug for the treatment of urinary urge incontinence [59].

In order to model and understand these biological properties and to develop new chemotherapeutic agents based upon the 1,4-DHP compounds, significant effort has been devoted to establish effective methods for their synthesis. Generally, 1,4-DHPs were synthesized by Hantzsch method [60], which involves cyclocondensation of an aldehyde, a β-ketoester and ammonia either in acetic acid or under reflux in alcohols for long reaction times which typically leads to low yields [46, 61, 62]. Other methods comprise the use of microwaves [63–65], high temperatures at reflux [66–69], organocatalysts [70] and metal triflates [71].

Recently, DNA is an important drug target and it regulates many biochemical processes that occur in the cellular system. Small-molecule interactions with DNA continue to be intensely and widely studied for their usefulness as probes of cellular replication and transcriptional regulation and for their potential as pharmaceuticals [72–75]. In particular, designing of the compound based on their ability to cleave DNA is of great importance not only from the primary biological point of view

**219**

**Figure 2.**

*Therapeutic Significance of 1,4-Dihydropyridine Compounds as Potential Anticancer Agents*

but also in terms of photodynamic therapeutic approach to develop potent drugs [72–75]. 1,4-Dihydropyridine derivatives have attracted the attention of the chemists because of their diverse biological applications [76]. The biological significance of this class of compounds impelled us to extend this series by working on the synthesis and DNA photocleavage studies of 1,4-dihydropyridine derivatives. In this communication, synthesis of 1,4-dihydropyridine derivatives and their DNA

In literature, there are several methods known for the synthesis of 1,4-dihydropyridine derivatives. In continuation of our program on the chemistry of nano material, herein we report an efficient microwave method for the synthesis of crystalline ZnO-NPs. The ZnO used in this work was synthesized according to a modified method. The prepared crystalline ZnO-nano-particle was characterized using powder XRD, SEM, EDX (**Figure 2**). Our synthetic approach started with the condensation of 1 equiv. of benzaldehyde **1a** with 2 equiv. of ethyl acetoacetate **2a** and 2 equiv. of NH4OAc **3a** in the presence of ZnO-Nps resulted in the formation of Hantzsch 1,4-dihydropyridine **4a** (**Figure 3**). The reaction was complete in 5 min under microwave irradiation and the product was isolated by the usual work-up, in 90% yield and high purity. Under similar conditions, various substituted aromatic aldehydes carrying either electron-donating or -withdrawing substituents reacted with 1,3-diketones to form 1,4-DHPs in good to excellent yields, and the results are

A microwave irradiation-assisted process very often minimizes the formation of byproducts and requires much less time than thermal methods. The main benefits of performing reactions under controlled conditions in sealed vessels are the significant rate enhancements and the higher product yields that can frequently be achieved. Therefore, in continuation of our studies on microwave synthesis of nano-materials [77–81], we have attempted to develop a rapid, microwaveassisted protocol for the synthesis of 1,4-DHPs using crystalline ZnO-nano

The DNA cleavage of 1,4-DHP derivatives were studied by agarose gel electrophoresis. When circular plasmid DNA was subjected to electrophoresis, relatively fast migration was observed for the intact supercoiled DNA (type I). If scission occurs on one strand (nicking), the supercoiled DNA will relax to generate a slower moving open circular form (type II). If both strands are cleaved, a linear form

*(a) Powder XRD of obtained ZnO nano particles by microwave method; (b) SEM images of ZnO-NPs;* 

*(c) EDX analysis spectrum of obtained ZnO nano particles by microwave method.*

photocleavage studies and molecular docking have been reported.

*DOI: http://dx.doi.org/10.5772/intechopen.89860*

summarized in **Table 1**.

catalyst (**Figure 3**).

**Figure 1.** *Drugs containing 1,4-DHP moieties.*

#### *Therapeutic Significance of 1,4-Dihydropyridine Compounds as Potential Anticancer Agents DOI: http://dx.doi.org/10.5772/intechopen.89860*

but also in terms of photodynamic therapeutic approach to develop potent drugs [72–75]. 1,4-Dihydropyridine derivatives have attracted the attention of the chemists because of their diverse biological applications [76]. The biological significance of this class of compounds impelled us to extend this series by working on the synthesis and DNA photocleavage studies of 1,4-dihydropyridine derivatives. In this communication, synthesis of 1,4-dihydropyridine derivatives and their DNA photocleavage studies and molecular docking have been reported.

In literature, there are several methods known for the synthesis of 1,4-dihydropyridine derivatives. In continuation of our program on the chemistry of nano material, herein we report an efficient microwave method for the synthesis of crystalline ZnO-NPs. The ZnO used in this work was synthesized according to a modified method. The prepared crystalline ZnO-nano-particle was characterized using powder XRD, SEM, EDX (**Figure 2**). Our synthetic approach started with the condensation of 1 equiv. of benzaldehyde **1a** with 2 equiv. of ethyl acetoacetate **2a** and 2 equiv. of NH4OAc **3a** in the presence of ZnO-Nps resulted in the formation of Hantzsch 1,4-dihydropyridine **4a** (**Figure 3**). The reaction was complete in 5 min under microwave irradiation and the product was isolated by the usual work-up, in 90% yield and high purity. Under similar conditions, various substituted aromatic aldehydes carrying either electron-donating or -withdrawing substituents reacted with 1,3-diketones to form 1,4-DHPs in good to excellent yields, and the results are summarized in **Table 1**.

A microwave irradiation-assisted process very often minimizes the formation of byproducts and requires much less time than thermal methods. The main benefits of performing reactions under controlled conditions in sealed vessels are the significant rate enhancements and the higher product yields that can frequently be achieved. Therefore, in continuation of our studies on microwave synthesis of nano-materials [77–81], we have attempted to develop a rapid, microwaveassisted protocol for the synthesis of 1,4-DHPs using crystalline ZnO-nano catalyst (**Figure 3**).

The DNA cleavage of 1,4-DHP derivatives were studied by agarose gel electrophoresis. When circular plasmid DNA was subjected to electrophoresis, relatively fast migration was observed for the intact supercoiled DNA (type I). If scission occurs on one strand (nicking), the supercoiled DNA will relax to generate a slower moving open circular form (type II). If both strands are cleaved, a linear form

#### **Figure 2.**

*(a) Powder XRD of obtained ZnO nano particles by microwave method; (b) SEM images of ZnO-NPs; (c) EDX analysis spectrum of obtained ZnO nano particles by microwave method.*

*Organic Synthesis - A Nascent Relook*

counterparts [29, 39–42].

synthesis of cyclic urea [37], N-formylation of amines [38]. In particular crystalline nano-ZnO oxide exhibit better catalytic activity compared to their bulk sized

dants [58] and a drug for the treatment of urinary urge incontinence [59].

reflux [66–69], organocatalysts [70] and metal triflates [71].

In order to model and understand these biological properties and to develop new chemotherapeutic agents based upon the 1,4-DHP compounds, significant effort has been devoted to establish effective methods for their synthesis. Generally, 1,4-DHPs were synthesized by Hantzsch method [60], which involves cyclocondensation of an aldehyde, a β-ketoester and ammonia either in acetic acid or under reflux in alcohols for long reaction times which typically leads to low yields [46, 61, 62]. Other methods comprise the use of microwaves [63–65], high temperatures at

Recently, DNA is an important drug target and it regulates many biochemical processes that occur in the cellular system. Small-molecule interactions with DNA continue to be intensely and widely studied for their usefulness as probes of cellular replication and transcriptional regulation and for their potential as pharmaceuticals [72–75]. In particular, designing of the compound based on their ability to cleave DNA is of great importance not only from the primary biological point of view

In recent years, much attention has been directed toward the synthesis of dihydropyridine compounds owing to their tremendous application in various research fields including biological science and medicinal chemistry [43, 44]. Many DHPs are already commercial products such as: amlodipine, felodipine, isradipine, lacidipine, nicardipine, nitrendipine, nifedipine and nimodipine B, of which nitrendipine and nemadipine B exhibit potent calcium channel blocking activities [45–49] (**Figure 1**) and have emerged as one of the most important classes of drugs for the treatment of cardiovascular diseases [50, 51]. Moreover dihydropyridine derivatives possess a variety of biological activities like, geroprotective, hepatoprotective, anti-atherosclerotic, antitumor, and antidiabetic activities [46, 52, 53]. Widespread studies have uncovered that dihydropyridine unit containing compounds exhibit various medicinal functions such as neuroprotectant, platelet anti-aggregatory activity, cerebral anti ischemic activity in the treatment of Alzheimer's disease, chemosensitizer in tumor therapy [54–56]. Drug-resistance modifiers [57], antioxi-

**218**

**Figure 1.**

*Drugs containing 1,4-DHP moieties.*

**Figure 3.** *Synthesis of 1,4-dihydropyridines.*


*a All the products were characterized by 1H NMR and 13C NMR studies and compared with the literature mps. b Yields of isolated products*

#### **Table 1.**

*Synthesis of 1,4-dihydropyridines.*

(type III) that migrates between type I and type II will be generated [82–85]. The conversion of type I (supercoiled) to type II (nicked circular) was observed with different concentration of 1,4-DHP and irradiated for 2 h, in 1:9 DMSO/trisbuffer (20 μM, pH- 7.2) at 365 nm. No DNA cleavage was observed for the control in which 1,4-DHP was absent (lane 1) (**Figure 4)**. With increasing concentration of these 1,4-DHP the amount of type I of pUC 19 DNA diminished gradually, whereas type II increased (**Figure 4**).

At 40 μM concentration, the Compound (**4c**) can promote only 30% conversion of DNA from type I to II (**Figure 5)**. At the concentration of 80 μM, compound (**4c**)

**221**

II (**Figure 5**).

**Figure 4.**

*80 μM (4c).*

**Figure 5.**

of photoirradiation [86].

*Therapeutic Significance of 1,4-Dihydropyridine Compounds as Potential Anticancer Agents*

*Light-induced DNA cleavage by 1,4-DHP. The 1,4-DHP was irradiated with UV light at 365 nm. Lane; 1: Control DNA (with out compound), lane; 2: 20 μM (4c), lane; 3: 40 μM (4c), lane; 4: 60 μM (4c), lane; 5:* 

can almost promote the about 80% conversion of DNA from type I to II (**Figure 5**). The cleavage potential of the test compounds were assessed by comparing the bands appeared in control and test compounds at 80 μM concentration. However, other derivatives exhibits much lower cleaving efficiency for pUC 19 DNA. Even at the concentration of 80 μM, it can promote only 40% conversion of DNA from type I to

*Light-induced DNA cleavage by 1,4-DHP. The 1,4-DHP was irradiated with UV light at 365 nm. Lane; 1: Control DNA (with out compound), lane; 2: 40 μM (4a), lane; 3: 40 μM (4b), lane; 4: 40 μM (4c), lane; 5:* 

*40 μM (4d), lane; 5: 40 μM (4e), lane; 5: 40 μM (4f), lane; 5: 40 μM (4 g).*

But at higher concentrations around 130 μM, the compounds get precipitated and there is no moment in the DNA. The image (**Figure 6**) clearly demonstrates that compounds (**4b, 4c, 4d, 4e, 4f** and **4 g**) shows DNA cleavage of pUC19 DNA at 80 μM concentration. The results indicated that compounds bearing –OCH3 and *–*OH at -*para* position of phenyl ring (C-6) did cleave the DNA completely, other compounds have displayed nearly complete cleavage of DNA. Overall, it indicates that, the alkoxy groups are highly reactive radicals, which abstracts hydrogen atoms efficiently at C-4′ of 2-deoxyribose. It is of interest to note that hydroxyl group has been reported to bring about oxygen radical mediated DNA damage in the presence

The structure–activity relationship studies of 1,4-DHPs with regard to DNA photocleavage studies shows that, the changes in the substitution pattern at C-3, C-4, and C-5 positions alter the 1,4-DHP ring. Osiris Property Explorer is one such knowledge based activity prediction tool which predicts drug likeliness, drug score and undesired properties such as mutagenic, tumorigenic, irritant and reproductive effect of novel compounds based on chemical fragment data of available drugs and non-drugs as reported (**Table 2**) [87]. It was observed that, the compounds having aliphatic groups such as –CH3, –COOCH3, –COOC2H5 and –COOC(CH3)3, attached to C-2 and C-3 of 1,4-DHP exhibited good activity. Other derivatives possessing, an electron-donating substituent, such as hydroxy and methoxy group on the phenyl ring (C-6) increases DNA photocleavage activity. A lone pair of electrons on oxygen atom of methoxy group delocalizes into the π space of benzene ring,

*DOI: http://dx.doi.org/10.5772/intechopen.89860*

*Therapeutic Significance of 1,4-Dihydropyridine Compounds as Potential Anticancer Agents DOI: http://dx.doi.org/10.5772/intechopen.89860*

#### **Figure 4.**

*Organic Synthesis - A Nascent Relook*

**Figure 3.**

*Synthesis of 1,4-dihydropyridines.*

**220**

*a*

*b*

**Table 1.**

II increased (**Figure 4**).

*Yields of isolated products*

*Synthesis of 1,4-dihydropyridines.*

(type III) that migrates between type I and type II will be generated [82–85]. The conversion of type I (supercoiled) to type II (nicked circular) was observed with different concentration of 1,4-DHP and irradiated for 2 h, in 1:9 DMSO/trisbuffer (20 μM, pH- 7.2) at 365 nm. No DNA cleavage was observed for the control in which 1,4-DHP was absent (lane 1) (**Figure 4)**. With increasing concentration of these 1,4-DHP the amount of type I of pUC 19 DNA diminished gradually, whereas type

*All the products were characterized by 1H NMR and 13C NMR studies and compared with the literature mps.* 

**Entrya R R1 Products Entrya Yield (%)b** C6H5 *t*-Bu **4a 1** 90 4*-*MeO-C6H5 *t*-Bu **4b 2** 95 4*-*OH-C6H5 *t*-Bu **4c 3** 95 4*-*F-C6H5 *t*-Bu **4d 4** 95 4*-*Cl-C6H5 *t*-Bu **4e 5** 90 4*-*NO2-C6H5 *t*-Bu **4f 6** 95 C6H5 Et **4 g 7** 90 4*-*MeO-C6H5 Et **4 h 8** 95 4*-*OH-C6H5 Et **4i 9** 92 4*-*F-C6H5 Et **4j 10** 92 4*-*Cl-C6H5 Et **4 k 11** 90 4*-*NO2-C6H5 Et **4 l 12** 90 C6H5 Me **4 m 13** 90 4*-*MeO-C6H5 Me **4n 14** 87 4*-*OH-C6H5 Me **4o 15** 90 4*-*F-C6H5 Me **4p 16** 90 4*-*Cl-C6H5 Me **4q 17** 90 4*-*NO2-C6H5 Me **4r 18** 90

At 40 μM concentration, the Compound (**4c**) can promote only 30% conversion of DNA from type I to II (**Figure 5)**. At the concentration of 80 μM, compound (**4c**)

*Light-induced DNA cleavage by 1,4-DHP. The 1,4-DHP was irradiated with UV light at 365 nm. Lane; 1: Control DNA (with out compound), lane; 2: 20 μM (4c), lane; 3: 40 μM (4c), lane; 4: 60 μM (4c), lane; 5: 80 μM (4c).*

#### **Figure 5.**

*Light-induced DNA cleavage by 1,4-DHP. The 1,4-DHP was irradiated with UV light at 365 nm. Lane; 1: Control DNA (with out compound), lane; 2: 40 μM (4a), lane; 3: 40 μM (4b), lane; 4: 40 μM (4c), lane; 5: 40 μM (4d), lane; 5: 40 μM (4e), lane; 5: 40 μM (4f), lane; 5: 40 μM (4 g).*

can almost promote the about 80% conversion of DNA from type I to II (**Figure 5**). The cleavage potential of the test compounds were assessed by comparing the bands appeared in control and test compounds at 80 μM concentration. However, other derivatives exhibits much lower cleaving efficiency for pUC 19 DNA. Even at the concentration of 80 μM, it can promote only 40% conversion of DNA from type I to II (**Figure 5**).

But at higher concentrations around 130 μM, the compounds get precipitated and there is no moment in the DNA. The image (**Figure 6**) clearly demonstrates that compounds (**4b, 4c, 4d, 4e, 4f** and **4 g**) shows DNA cleavage of pUC19 DNA at 80 μM concentration. The results indicated that compounds bearing –OCH3 and *–*OH at -*para* position of phenyl ring (C-6) did cleave the DNA completely, other compounds have displayed nearly complete cleavage of DNA. Overall, it indicates that, the alkoxy groups are highly reactive radicals, which abstracts hydrogen atoms efficiently at C-4′ of 2-deoxyribose. It is of interest to note that hydroxyl group has been reported to bring about oxygen radical mediated DNA damage in the presence of photoirradiation [86].

The structure–activity relationship studies of 1,4-DHPs with regard to DNA photocleavage studies shows that, the changes in the substitution pattern at C-3, C-4, and C-5 positions alter the 1,4-DHP ring. Osiris Property Explorer is one such knowledge based activity prediction tool which predicts drug likeliness, drug score and undesired properties such as mutagenic, tumorigenic, irritant and reproductive effect of novel compounds based on chemical fragment data of available drugs and non-drugs as reported (**Table 2**) [87]. It was observed that, the compounds having aliphatic groups such as –CH3, –COOCH3, –COOC2H5 and –COOC(CH3)3, attached to C-2 and C-3 of 1,4-DHP exhibited good activity. Other derivatives possessing, an electron-donating substituent, such as hydroxy and methoxy group on the phenyl ring (C-6) increases DNA photocleavage activity. A lone pair of electrons on oxygen atom of methoxy group delocalizes into the π space of benzene ring,

#### **Figure 6.**

*Light-induced DNA cleavage by 1,4-DHP. The 1,4-DHP was irradiated with UV light at 365 nm. Lane; 1: Control DNA (with out compound), lane; 2: 80 μM (4a), lane; 3: 80 μM (4b), lane; 4: 80 μM (4c), lane; 5: 80 μM (4d), lane; 5: 80 μM (4e), lane; 5: 80 μM (4f), lane; 5: 80 μM (4 g).*


*a Ranking as (+) no bad effect, (+/−) medium bad effect, (−) bad effect.* 

*b M (mutagenic effect);* 

*c T (tumorigenic effect);* 

*d I (irritant effect);* 

*e R (reproductive effect).*

#### **Table 2.**

*Drug likeliness properties of 1,4-dihydro pyridines according to Osiris property explorer tool.*

thereby increasing the activity. Similarly, electron-withdrawing substituent's, such as 4-fluorophenyl, 4-chloro phenyl of 1,4-DHP lower the activity. These results indicate that, the alkoxy substituent's and nitrogen of pyridine ring in the 1,4-DHP structure are the responsible for DNA cleavage.

In order to rationalize the observed spectroscopic results and to get more insight into the intercalation modality, the 1,4-DHP (**4a**–**r**) were successively docked [88–90] within the DNA duplex of sequence d(CGCGAATTCGCG)2 dodecamer

**223**

**Table 3.**

*Molecular docking studies of 1,4-dihydropyridines.*

*Therapeutic Significance of 1,4-Dihydropyridine Compounds as Potential Anticancer Agents*

(PDB ID: 1BNA) in order to predict the chosen binding site along with preferred orientation of the ligand inside the DNA minor groove. All synthesized 1,4-DHP derivatives were drawn in ChemSketch and structures were saved in .mol format. Afterwards the .mol format was used in Hyperchem-7, to adjust their fragments, followed by total energy minimization of ligands so that they can attain a stable

Protein 3D structure of B-DNA was obtained from RCSB PDB (an information portal to biological macromolecular structures). The water molecules were removed from the file, and the protein was protonated in 3D to add polar hydrogen's. Binding pocket was identified using site finder, and the respective residues were selected. Docking parameters were set to default values and scoring algorithm, the docking runs were retained to 30 conformations per ligand. The docked protein structures were saved in .pdb format, and ligand's conformations were investigated one by one. Complexes with best conformations were selected on the basis of highest score,

The synthesized organic compounds perform their biological activity more efficiently by binding respective protein or DNA at their specific binding site. Identification of interacting residues with ligands is a necessary step toward rational drug designing,

Molecular docking was carried out between rigid receptor protein and the flexible ligands. **Table 3** shows the details of the docking results including RMSD and binding energy values of protein–ligand complexes. The ligands (**4b, 4c, 4 h, 4i, 4n** and **4o**) bind strongly to B-DNA as inferred by their minimum binding energy

**Figure 8** shows the position of active site in the helical structure of DNA and it also shows that all docked ligands clustered inside the pocket. **Figure 8** exhibited

**Products Docking energy (Kcal/mol) Inhibition constant (M) RMSD 4a** −6.23 4.35 × 10<sup>−</sup><sup>7</sup> 2.5 **4b** −24.12 1.81 × 10<sup>−</sup><sup>16</sup> 1.1 **4c** −21.74 1.96 × 10<sup>−</sup><sup>16</sup> 1.5 **4d** −5.72 5.96 × 10<sup>−</sup><sup>7</sup> 3.4 **4e** −7.24 6.31 × 10<sup>−</sup><sup>7</sup> 3.4 **4f** −6.85 4.88 × 10<sup>−</sup><sup>7</sup> 3.8 **4 g** −7.41 4.51 × 10<sup>−</sup><sup>7</sup> 2.0 **4 h** −22.35 1.92 × 10<sup>−</sup><sup>16</sup> 1.0 **4i** −19.81 2.32 × 10<sup>−</sup><sup>16</sup> 1.0 **4j** −6.34 5.88 × 10<sup>−</sup><sup>7</sup> 2.1 **4 k** −6.68 6.76 × 10<sup>−</sup><sup>7</sup> 2.1 **4 l** −8.22 5.18 × 10<sup>−</sup><sup>7</sup> 2.4 **4 m** −7.55 4.68 × 10<sup>−</sup><sup>7</sup> 2.3 **4n** −22.64 1.96 × 10<sup>−</sup><sup>16</sup> 1.1 **4o** −20.36 2.18 × 10<sup>−</sup><sup>16</sup> 1.0 **4p** −6.78 6.20 × 10<sup>−</sup><sup>7</sup> 1.5 **4q** −6.52 7.15 × 10<sup>−</sup><sup>7</sup> 1.8 **4r** −7.89 6.32 × 10<sup>−</sup><sup>7</sup> 1.5

*DOI: http://dx.doi.org/10.5772/intechopen.89860*

conformation and the file was saved in .pdb format.

lowest binding energy and minimum RMSD values [91].

understanding of molecular pathway and mechanistic action of protein.

values, that is, −13.8, −12.9 and − 12.3 kcal/mol, respectively (**Figure 7**).

#### *Therapeutic Significance of 1,4-Dihydropyridine Compounds as Potential Anticancer Agents DOI: http://dx.doi.org/10.5772/intechopen.89860*

(PDB ID: 1BNA) in order to predict the chosen binding site along with preferred orientation of the ligand inside the DNA minor groove. All synthesized 1,4-DHP derivatives were drawn in ChemSketch and structures were saved in .mol format. Afterwards the .mol format was used in Hyperchem-7, to adjust their fragments, followed by total energy minimization of ligands so that they can attain a stable conformation and the file was saved in .pdb format.

Protein 3D structure of B-DNA was obtained from RCSB PDB (an information portal to biological macromolecular structures). The water molecules were removed from the file, and the protein was protonated in 3D to add polar hydrogen's. Binding pocket was identified using site finder, and the respective residues were selected. Docking parameters were set to default values and scoring algorithm, the docking runs were retained to 30 conformations per ligand. The docked protein structures were saved in .pdb format, and ligand's conformations were investigated one by one. Complexes with best conformations were selected on the basis of highest score, lowest binding energy and minimum RMSD values [91].

The synthesized organic compounds perform their biological activity more efficiently by binding respective protein or DNA at their specific binding site. Identification of interacting residues with ligands is a necessary step toward rational drug designing, understanding of molecular pathway and mechanistic action of protein.

Molecular docking was carried out between rigid receptor protein and the flexible ligands. **Table 3** shows the details of the docking results including RMSD and binding energy values of protein–ligand complexes. The ligands (**4b, 4c, 4 h, 4i, 4n** and **4o**) bind strongly to B-DNA as inferred by their minimum binding energy values, that is, −13.8, −12.9 and − 12.3 kcal/mol, respectively (**Figure 7**).

**Figure 8** shows the position of active site in the helical structure of DNA and it also shows that all docked ligands clustered inside the pocket. **Figure 8** exhibited


#### **Table 3.**

*Organic Synthesis - A Nascent Relook*

**Figure 6.**

**222**

*a*

*b*

*c*

*d*

*e*

**Table 2.**

*M (mutagenic effect);* 

*T (tumorigenic effect);* 

*R (reproductive effect).*

*I (irritant effect);* 

thereby increasing the activity. Similarly, electron-withdrawing substituent's, such as 4-fluorophenyl, 4-chloro phenyl of 1,4-DHP lower the activity. These results indicate that, the alkoxy substituent's and nitrogen of pyridine ring in the 1,4-DHP

*Drug likeliness properties of 1,4-dihydro pyridines according to Osiris property explorer tool.*

*Light-induced DNA cleavage by 1,4-DHP. The 1,4-DHP was irradiated with UV light at 365 nm. Lane; 1: Control DNA (with out compound), lane; 2: 80 μM (4a), lane; 3: 80 μM (4b), lane; 4: 80 μM (4c), lane; 5:* 

**likeness**

**4a** 329 3.29 2.41 0.77 (+) (+) (+) (+) **4b** 359 3.22 2.34 0.75 (+) (+) (+) (+) **4c** 345 2.94 2.48 0.79 (+) (+) (+) (+) **4d** 347 3.39 1.65 0.70 (+) (+) (+) (+) **4e** 419 5.37 −17.92 0.22 (+) (+) (+) (+) **4f** 430 4.17 −19.36 0.10 (−) (+) (+) (−) **4 g** 301 2.48 4.04 0.87 (+) (+) (+) (+) **4 h** 331 2.41 3.87 0.51 (+) (+) (+) (+) **4i** 317 2.13 4.08 0.53 (+) (+) (+) (+) **4j** 319 2.58 3.29 0.50 (+) (+) (+) (+) **4 k** 363 3.89 3.33 0.68 (+) (+) (+) (+) **4 l** 374 2.69 1.92 0.25 (−) (+) (+) (−) **4 m** 269 2.98 4.09 0.50 (+) (+) (+) (+) **4n** 299 2.91 3.94 0.49 (+) (+) (+) (−) **4o** 285 2.63 4.14 0.51 (+) (+) (+) (+) **4p** 287 3.08 3.42 0.47 (+) (+) (+) (−) **4q** 335 3.08 4.97 0.48 (+) (+) (+) (−) **4r** 346 1.88 3.50 0.30 (−) (+) (+) (−)

**Drugscore**

**Toxicity risksa**

**<sup>d</sup> Re**

**Mb Tc I**

*80 μM (4d), lane; 5: 80 μM (4e), lane; 5: 80 μM (4f), lane; 5: 80 μM (4 g).*

**Compounds Mol. wt C log P Drug-**

In order to rationalize the observed spectroscopic results and to get more insight

into the intercalation modality, the 1,4-DHP (**4a**–**r**) were successively docked [88–90] within the DNA duplex of sequence d(CGCGAATTCGCG)2 dodecamer

structure are the responsible for DNA cleavage.

*Ranking as (+) no bad effect, (+/−) medium bad effect, (−) bad effect.* 

*Molecular docking studies of 1,4-dihydropyridines.*

#### **Figure 7.**

*1,4-DHP was successively docked within the DNA duplex of sequence d(CGCGAATTCGCG)2 dodecamer (PDB ID: 1BNA).*

**Figure 8.** *Interaction of 1,4-DHP with DNA duplex of sequence d(CGCGAATTCGCG)2 dodecamer (PDB ID: 1BNA).*

the hydrogen bond interaction of **4c** and **4d** with key residues in active site inside the helical structure of DNA. In this model, it is clearly indicated that the compound **4c** formed hydrogen bonded between the –OH and N1 of thymine, which is DT7 and DT19 with the bond length of 2.02 and 2.05 Ǻ respectively. Moreover, the other derivatives of 1,4-DHP formed less H-bond interaction with the DNA due to the orientation of aromatic ring involved in van der Waals interactions (Wireframe model) and flat hydrophobic regions of the binding sites of DNA (**Table 3**). These results demonstrated the in silico molecular docking studies of 1,4-DHPs with B-DNA suggested that 1,4-DHPs possess the potential to disturb hydrophobic and H-bond interactions thereby affecting the stability of attachment of B-DNA, and may be effective for cancer cell lines.

**225**

*Therapeutic Significance of 1,4-Dihydropyridine Compounds as Potential Anticancer Agents*

All the chemicals used in the present study are of AR grade. Whenever analytical grade chemicals were not available, laboratory grade chemicals were purified and used. AlCl3, ZnCl2, Yb(OTF)3, FeCl3 and Zinc acetate obtained from Merck chemicals and are directly used without further purification. Melting points were recorded on an open capillary tube with a Buchi melting point apparatus and are

In a typical synthesis process, zinc acetate dihydrate (1.1 g, 0.01 M) was dissolved in 20 mL of ethanol with constant stirring for 20 min. Then KOH (0.178 M) was added into the above mixed solution. After further stirring for 5 min, the reaction mixture was put into a CEM microwave synthesizer to irradiate for 10 min with

tion of reaction, the white precipitate was collected by centrifugation, washed twice

Crystalline structure of the prepared ZnO-Nps was determined by powder X-ray

H- NMR spectra were obtained using a 400 MHz on a Bruker spec-

. After comple-

*DOI: http://dx.doi.org/10.5772/intechopen.89860*

trometer (chemical shifts in δ ppm).

*2.1.1 General procedure for the preparation of ZnO-Nps*

the power set at 150 W, Temperature at 150°C and Pressure 150 C0

with deionized water, ethanol and dried in vacuum oven at 60°C for 5 h.

*2.1.2 General procedure for the synthesis of 1,4-DHP by microwave method*

**4a. Di-tert-Butyl − 1,4-dihydro-2,6-dimethyl-4-phenylpyridine-3,5-**

4.83 (s, 1H), 5.58 (brs, 1H), 7.05-7.10 (m, 1H), 7.10-7.20 (m, 2H), 7.23-7.30 (m, 2H); 13C NMR (125 MHz, CDCl3) δ 20.0, 28.4, 40.0, 80.0, 105.5, 125.6, 127.5, 128.5, 129.2,

to obtain desired product (**Figure 3**, **Table 1**).

A mixture of aromatic aldehydes **1a** (5 mmol), ethyl acetoacetate **2** (10 mmol), and ammonium acetate **3** (10 mmol) and ZnO (10 mol %) was taken in ethanol (20 mL) and the mixture was heated at microwave irradiation for 5 min (monitored by TLC after 5 min. interval). After 5 min, the reaction mixture was cooled to room temperature and then it was poured into cold water. The product was extracted with ethyl acetate. The organic layer was washed with brine, water and dried over anhydrous Na2SO4. The crude product thus obtained was recrystallized from EtOH

H NMR (500 MHz, CDCl3) δ 1.43 (s, 18H), 2.30 (s, 6H),

diffraction (XRD). The strong intensity and narrow width of diffraction peaks indicate the high crystallinity of the prepared ZnO-Nps (**Figure 2a**). The peaks are indexed as 31.82° (100), 34.54° (002), 36.42° (101), 47.46° (102), 56.74° (110), 62.92° (103), 66.06° (200), 68.42° (112), 69.06° (201) and 78.82° (202) respectively. This revealed that the resultant nanoparticles were pure ZnO with a hexagonal structure (JCPDS 36-1451). No impurities could be detected in this pattern, which implies hexagonal phase ZnO nanoparticles could be obtained under the current microwave method. X-ray diffraction shows that metal oxide is pure ZnO having hexagonal structure. Sharpness of the peaks shows good crystal growth of the oxide particles. Average particle sizes of the ZnO have been calculated using from high intensity

**2. Experimental**

uncorrected. 1

peak using Image J.

**dicarboxylate**

143.0, 147.5, 167.3.

Solid: MP 180–182°C; <sup>1</sup>

**2.1 Materials and method**

## **2. Experimental**

*Organic Synthesis - A Nascent Relook*

**224**

**Figure 7.**

**Figure 8.**

*(PDB ID: 1BNA).*

may be effective for cancer cell lines.

the hydrogen bond interaction of **4c** and **4d** with key residues in active site inside the helical structure of DNA. In this model, it is clearly indicated that the compound **4c** formed hydrogen bonded between the –OH and N1 of thymine, which is DT7 and DT19 with the bond length of 2.02 and 2.05 Ǻ respectively. Moreover, the other derivatives of 1,4-DHP formed less H-bond interaction with the DNA due to the orientation of aromatic ring involved in van der Waals interactions (Wireframe model) and flat hydrophobic regions of the binding sites of DNA (**Table 3**). These results demonstrated the in silico molecular docking studies of 1,4-DHPs with B-DNA suggested that 1,4-DHPs possess the potential to disturb hydrophobic and H-bond interactions thereby affecting the stability of attachment of B-DNA, and

*Interaction of 1,4-DHP with DNA duplex of sequence d(CGCGAATTCGCG)2 dodecamer (PDB ID: 1BNA).*

*1,4-DHP was successively docked within the DNA duplex of sequence d(CGCGAATTCGCG)2 dodecamer* 

## **2.1 Materials and method**

All the chemicals used in the present study are of AR grade. Whenever analytical grade chemicals were not available, laboratory grade chemicals were purified and used. AlCl3, ZnCl2, Yb(OTF)3, FeCl3 and Zinc acetate obtained from Merck chemicals and are directly used without further purification. Melting points were recorded on an open capillary tube with a Buchi melting point apparatus and are uncorrected. 1 H- NMR spectra were obtained using a 400 MHz on a Bruker spectrometer (chemical shifts in δ ppm).

## *2.1.1 General procedure for the preparation of ZnO-Nps*

In a typical synthesis process, zinc acetate dihydrate (1.1 g, 0.01 M) was dissolved in 20 mL of ethanol with constant stirring for 20 min. Then KOH (0.178 M) was added into the above mixed solution. After further stirring for 5 min, the reaction mixture was put into a CEM microwave synthesizer to irradiate for 10 min with the power set at 150 W, Temperature at 150°C and Pressure 150 C0 . After completion of reaction, the white precipitate was collected by centrifugation, washed twice with deionized water, ethanol and dried in vacuum oven at 60°C for 5 h.

Crystalline structure of the prepared ZnO-Nps was determined by powder X-ray diffraction (XRD). The strong intensity and narrow width of diffraction peaks indicate the high crystallinity of the prepared ZnO-Nps (**Figure 2a**). The peaks are indexed as 31.82° (100), 34.54° (002), 36.42° (101), 47.46° (102), 56.74° (110), 62.92° (103), 66.06° (200), 68.42° (112), 69.06° (201) and 78.82° (202) respectively. This revealed that the resultant nanoparticles were pure ZnO with a hexagonal structure (JCPDS 36-1451). No impurities could be detected in this pattern, which implies hexagonal phase ZnO nanoparticles could be obtained under the current microwave method. X-ray diffraction shows that metal oxide is pure ZnO having hexagonal structure. Sharpness of the peaks shows good crystal growth of the oxide particles. Average particle sizes of the ZnO have been calculated using from high intensity peak using Image J.

## *2.1.2 General procedure for the synthesis of 1,4-DHP by microwave method*

A mixture of aromatic aldehydes **1a** (5 mmol), ethyl acetoacetate **2** (10 mmol), and ammonium acetate **3** (10 mmol) and ZnO (10 mol %) was taken in ethanol (20 mL) and the mixture was heated at microwave irradiation for 5 min (monitored by TLC after 5 min. interval). After 5 min, the reaction mixture was cooled to room temperature and then it was poured into cold water. The product was extracted with ethyl acetate. The organic layer was washed with brine, water and dried over anhydrous Na2SO4. The crude product thus obtained was recrystallized from EtOH to obtain desired product (**Figure 3**, **Table 1**).

## **4a. Di-tert-Butyl − 1,4-dihydro-2,6-dimethyl-4-phenylpyridine-3,5 dicarboxylate**

Solid: MP 180–182°C; <sup>1</sup> H NMR (500 MHz, CDCl3) δ 1.43 (s, 18H), 2.30 (s, 6H), 4.83 (s, 1H), 5.58 (brs, 1H), 7.05-7.10 (m, 1H), 7.10-7.20 (m, 2H), 7.23-7.30 (m, 2H); 13C NMR (125 MHz, CDCl3) δ 20.0, 28.4, 40.0, 80.0, 105.5, 125.6, 127.5, 128.5, 129.2, 143.0, 147.5, 167.3.

## **4b. Di-tert-butyl 4-(4-methoxyphenyl)-l,4-dihydro-2,6-dimethylpyridine-3,5-dicarboxylate**

Solid: MP 168–170°C; <sup>1</sup> H NMR (500 MHz, CDCl3) δ 1.40 (s, 18H), 2.25 (s, 6H), 3.86 (s, 3H), 4.81 (s, 1H), 5.51 (brs, 1H), 7.10-7.20 (d, 2H), 7.40-7.50 (d, 2H); 13C NMR (125 MHz, CDCl3) δ 19.8, 30.0, 41.0, 56.0, 81.0, 106.1, 125.6, 127.8, 135.0, 146.4, 153.2, 160.0, 167.5.

## **4c. Di-tert-butyl 4-(4-hydroxy-phenyl)-l,4-dihydro-2,6-dimethylpyridine-3,5-dicarboxylate**

Solid: MP 230–232°C; <sup>1</sup> H NMR (500 MHz, CDCl3) δ 1.36 (s, 18H), 2.28 (s, 6H), 4.90 (s, 1H), 5.56 (brs, 1H), 6.86-6.90 (d, 2H), 7.10-7.20 (d, 2H), 10.10 (s, 1H); 13C NMR (125 MHz, CDCl3) δ 24.5, 32.8, 45.3, 88.0, 108.4, 128.3, 131.0, 134.2, 134.6, 136.8, 148.4, 154.6, 172.6.

## **4d. Di-tert-butyl − 4-(4-fluorophenyl)-l,4-dihydro-2,6-dimethylpyridine-3,5-dicarboxylate**

Solid: MP 150–152°C; <sup>1</sup> H NMR (500 MHz, CDCl3) δ 1.43 (s, 18H), 2.30 (s, 6H), 4.81 (s, 1H), 5.50 (brs, 1H), 6.90-6.96 (d, 2H), 7.15-7.20 (d, 2H); 13C NMR (125 MHz, CDCl3) δ 20.0, 21.3, 38.9, 40.0, 79.8, 106.0, 114.2, 113.7, 125.4, 126.8, 129.2, 142.5, 143.2, 160.0, 162.5, 167.1.

## **4e. Di-tert-butyl 4-(4-chlorophenyl)-l,4-dihydro-2,6-dimethylpyridine-3,5-dicarboxylate**

Solid: MP 188–190°C; 1 U NMR (500 MHz, CDCl3) δ 1.38 (s, 18H), 2.25 (s, 6H), 4.85 (s, 1H), 5.50 (brs, 1H), 6.80-6.85 (d, 2H), 7.00-7.08 (d, 2H); 13C NMR (125 MHz, CDCl3) δ 24.3, 33.4, 45.1, 86.2, 108.8, 128.9, 130.4, 133.5, 134.3, 136.1, 148.6, 151.6, 172.4.

## **4 f. Di-tert-butyl − 4-(4-nitrophenyl)-l,4-dihydro-2,6-dimethylpyridine-3,5-dicarboxylate**

Solid: MP 176–178°C; <sup>1</sup> H NMR (500 MHz, CDCl3) δ 1.38 (s, 18H), 2.30 (s, 6H), 4.86 (s, 1H), 5.55 (brs, 1H), 7.00–7.10 (d, 2H), 7.15–7.25 (d, 2H); 13C NMR (125 MHz, CDCl3) δ 20.5, 22.4, 38.6, 40.1, 79.6, 107.0, 114.5, 114.6, 126.2, 126.8, 129.6, 142.6, 144.6, 161.0, 167.1.

## **4 g. 2,6-Dimethyl-4-phenyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid diethyl ester**

Solid: MP 158–160°C; <sup>1</sup> H NMR (CDCl3, 400 MHz): δ 1.20 (t, *J* = 9.7 Hz, 6H, 2CH3CH2), 2.28 (s, 6H, 2CH3), 4.10 (q, *J* = 6 Hz, 4H, 2CH3CH2), 5.00 (s, 1H, CH), 5.75 (s, 1H, NH), 7.10–7.50 (m, 5H); 13C NMR (CDCl3, 75 MHz): δ **=** 14.20 (C-3″), 19.5 (C-1″), 39.6 (C-4), 59.5 (C-2″), 104.1 (C-3 and C-5), 126.0 (C-4′), 127.8 (C-3′ and C-5′), 130.0 (C-2′ and C-6′), 143.8 (C-2 and C-6), 148.0 (C-1′), 168.0 (C-4″).

## **4 h. 2,6-Dimethyl-4-(4-methoxy-phenyl)-1,4-dihydro-pyridine-3,5 dicarboxylic acid diethyl ester**

Solid: MP 160–162°C; <sup>1</sup> H NMR (CDCl3, 400 MHz): δ 1.21 (t, *J* = 7.0 Hz, 6H), 2.30 (s, 6H), 3.78 (s, 3H), 4.10 (q, *J* = 6.3 Hz, 4H), 4.95 (s, 1H), 5.60 (s, 1H), 6.80

**227**

*Therapeutic Significance of 1,4-Dihydropyridine Compounds as Potential Anticancer Agents*

(d, *J* = 8.4 Hz, 2H), 7.18 (d, *J* = 8.7 Hz, 2H); 13C NMR (CDCl3, 75 MHz): δ 14.2, 19.6,

**4i. 2,6-Dimethyl-4-(4-hydroxy-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic** 

(s, 6H), 4.05 (q, *J* = 6.6 Hz, 4H), 4.90 (s, 1H), 5.61 (s, 1H), 6.70 (d, *J* = 8.7 Hz, 2H), 7.15 (d, *J* = 8.4 Hz, 2H), 9.90 (s, 1H); 13C NMR (CDCl3, 75 MHz): δ 14.0, 18.9, 39.0,

**4j. 2,6-Dimethyl-4-(4-fluoro-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic** 

Solid: MP 152–154°C; 1H NMR (CDCl3, 400 MHz): δ 1.10 (t, *J* = 7.2 Hz, 6H), 2.25 (s. 6H), 4.00 (q, *J* = 5.7 Hz, 4H), 4.88 (s, 1H), 5.68 (s, 1H), 6.80 (m, 2H), 7.15(m, 2H); 13C NMR (CDCl3, 75 MHz): δ 14.3, 19.7, 39.6, 60.1, 104.2, 114.4, 129.4, 129.7,

**4 k. 2,6-Dimethyl-4-(4-chloro-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic** 

**4 l. 2,6-Dimethyl-4-(4-nitro-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic** 

**4 m. 2,6-Dimethyl-4-phenyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid** 

75 MHz): δ = 19.7, 38.7, 50.5, 105.5, 126.2, 127.0, 128.0, 144.1, 147.1, 168.2.

**4n. 2,6-Dimethyl-4-(4-methoxy-phenyl)-1,4-dihydro-pyridine-3,5-**

75 MHz): δ 18.4, 38.4, 51.8, 103.1, 114.2, 128.4, 139.0, 144.2, 155.0, 167.6.

(s, 6H, 2CH3), 5.00 (s, 1H, CH), 5.80 (b, 1H), 7.20-7.56 (m, 5H); 13C NMR (CDCl3,

6H, 2CH3), 3.78 (s, 3H), 4.89 (s, 1H, CH), 5.30 (b, 1H), 6.80–7.10 (m, 4H); 13C NMR (CDCl3, 75 MHz): δ 19.5, 38.7, 55.1, 51.8, 104.4, 113.2, 128.9, 140.4, 143.4, 158.0, 167.7.

**4o. 2,6-Dimethyl-4-(4-hydroxy-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic** 

(s, 6H, 2CH3), 5.00 (s, 1H, CH), 5.40 (b, 1H), 6.95–7.20 (m, 4H); 13C NMR (CDCl3,

Solid: MP 153–155°C; 1H NMR (CDCl3, 400 MHz): δ 1.12 (t, *J* = 7.2 Hz, 6H), 2.35 (s. 6H), 4.12 (q, *J* = 5.7 Hz, 4H), 5.10 (s, 1H), 5.82 (s, 1H), 7.50 (d, 2H), 8.16 (d, 2H); 13C NMR (CDCl3, 75 MHz): δ 14.2, 18.6, 39.6, 60.0, 101.6, 116.8, 127.8, 129.3, 130.2,

Solid: MP 178–180°C; 1H NMR (CDCl3, 400 MHz): δ 1.26 (t, *J* = 7.2 Hz, 6H), 2.35 (s. 6H), 4.06 (q, *J* = 5.7 Hz, 4H), 5.08 (s, 1H), 5.76 (s, 1H), 7.48 (m, 2H), 8.02 (m, 2H); 13C NMR (CDCl3, 75 MHz): δ 14.2, 19.5, 39.6, 59.6, 104.2, 121.3, 1234.0, 128.4,

H NMR (CDCl3, 400 MHz): δ 2.30 (s, 6H, 2CH3), 3.66

H NMR (CDCl3, 400 MHz): δ 2.28 (s, 6H, 2CH3), 3.60 (s,

H NMR (CDCl3, 400 MHz): δ 2.26 (s, 6H, 2CH3), 3.63

H NMR (CDCl3, 400 MHz): δ 1.18 (t, *J* = 7.2 Hz, 6H), 2.28

*DOI: http://dx.doi.org/10.5772/intechopen.89860*

**acid diethyl ester**

**acid diethyl ester**

130.0, 143.5, 147.0, 167.5.

**acid diethyl ester**

144.8, 147.2, 166.8.

**acid diethyl ester**

136.8, 144.5, 147.8, 148.8, 167.5.

**dimethyl ester**

Solid: MP 194–196°C; <sup>1</sup>

Solid: MP 185–187°C; <sup>1</sup>

**acid dimethyl ester**

Solid: MP 228–230°C; <sup>1</sup>

**dicarboxylic acid dimethyl ester**

Solid: MP 238–240°C; <sup>1</sup>

38.8, 55.2, 59.8, 104.0, 115.0, 128.8, 140.0, 145.3, 156.7, 168.0.

59.0, 103.0, 114.2, 128.3, 139.4, 144.2, 154.1, 167.6.

*Therapeutic Significance of 1,4-Dihydropyridine Compounds as Potential Anticancer Agents DOI: http://dx.doi.org/10.5772/intechopen.89860*

(d, *J* = 8.4 Hz, 2H), 7.18 (d, *J* = 8.7 Hz, 2H); 13C NMR (CDCl3, 75 MHz): δ 14.2, 19.6, 38.8, 55.2, 59.8, 104.0, 115.0, 128.8, 140.0, 145.3, 156.7, 168.0.

## **4i. 2,6-Dimethyl-4-(4-hydroxy-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic acid diethyl ester**

Solid: MP 238–240°C; <sup>1</sup> H NMR (CDCl3, 400 MHz): δ 1.18 (t, *J* = 7.2 Hz, 6H), 2.28 (s, 6H), 4.05 (q, *J* = 6.6 Hz, 4H), 4.90 (s, 1H), 5.61 (s, 1H), 6.70 (d, *J* = 8.7 Hz, 2H), 7.15 (d, *J* = 8.4 Hz, 2H), 9.90 (s, 1H); 13C NMR (CDCl3, 75 MHz): δ 14.0, 18.9, 39.0, 59.0, 103.0, 114.2, 128.3, 139.4, 144.2, 154.1, 167.6.

## **4j. 2,6-Dimethyl-4-(4-fluoro-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic acid diethyl ester**

Solid: MP 152–154°C; 1H NMR (CDCl3, 400 MHz): δ 1.10 (t, *J* = 7.2 Hz, 6H), 2.25 (s. 6H), 4.00 (q, *J* = 5.7 Hz, 4H), 4.88 (s, 1H), 5.68 (s, 1H), 6.80 (m, 2H), 7.15(m, 2H); 13C NMR (CDCl3, 75 MHz): δ 14.3, 19.7, 39.6, 60.1, 104.2, 114.4, 129.4, 129.7, 130.0, 143.5, 147.0, 167.5.

## **4 k. 2,6-Dimethyl-4-(4-chloro-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic acid diethyl ester**

Solid: MP 153–155°C; 1H NMR (CDCl3, 400 MHz): δ 1.12 (t, *J* = 7.2 Hz, 6H), 2.35 (s. 6H), 4.12 (q, *J* = 5.7 Hz, 4H), 5.10 (s, 1H), 5.82 (s, 1H), 7.50 (d, 2H), 8.16 (d, 2H); 13C NMR (CDCl3, 75 MHz): δ 14.2, 18.6, 39.6, 60.0, 101.6, 116.8, 127.8, 129.3, 130.2, 144.8, 147.2, 166.8.

## **4 l. 2,6-Dimethyl-4-(4-nitro-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic acid diethyl ester**

Solid: MP 178–180°C; 1H NMR (CDCl3, 400 MHz): δ 1.26 (t, *J* = 7.2 Hz, 6H), 2.35 (s. 6H), 4.06 (q, *J* = 5.7 Hz, 4H), 5.08 (s, 1H), 5.76 (s, 1H), 7.48 (m, 2H), 8.02 (m, 2H); 13C NMR (CDCl3, 75 MHz): δ 14.2, 19.5, 39.6, 59.6, 104.2, 121.3, 1234.0, 128.4, 136.8, 144.5, 147.8, 148.8, 167.5.

### **4 m. 2,6-Dimethyl-4-phenyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid dimethyl ester**

Solid: MP 194–196°C; <sup>1</sup> H NMR (CDCl3, 400 MHz): δ 2.30 (s, 6H, 2CH3), 3.66 (s, 6H, 2CH3), 5.00 (s, 1H, CH), 5.80 (b, 1H), 7.20-7.56 (m, 5H); 13C NMR (CDCl3, 75 MHz): δ = 19.7, 38.7, 50.5, 105.5, 126.2, 127.0, 128.0, 144.1, 147.1, 168.2.

## **4n. 2,6-Dimethyl-4-(4-methoxy-phenyl)-1,4-dihydro-pyridine-3,5 dicarboxylic acid dimethyl ester**

Solid: MP 185–187°C; <sup>1</sup> H NMR (CDCl3, 400 MHz): δ 2.28 (s, 6H, 2CH3), 3.60 (s, 6H, 2CH3), 3.78 (s, 3H), 4.89 (s, 1H, CH), 5.30 (b, 1H), 6.80–7.10 (m, 4H); 13C NMR (CDCl3, 75 MHz): δ 19.5, 38.7, 55.1, 51.8, 104.4, 113.2, 128.9, 140.4, 143.4, 158.0, 167.7.

## **4o. 2,6-Dimethyl-4-(4-hydroxy-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic acid dimethyl ester**

Solid: MP 228–230°C; <sup>1</sup> H NMR (CDCl3, 400 MHz): δ 2.26 (s, 6H, 2CH3), 3.63 (s, 6H, 2CH3), 5.00 (s, 1H, CH), 5.40 (b, 1H), 6.95–7.20 (m, 4H); 13C NMR (CDCl3, 75 MHz): δ 18.4, 38.4, 51.8, 103.1, 114.2, 128.4, 139.0, 144.2, 155.0, 167.6.

*Organic Synthesis - A Nascent Relook*

**3,5-dicarboxylate**

146.4, 153.2, 160.0, 167.5.

**3,5-dicarboxylate**

136.8, 148.4, 154.6, 172.6.

**3,5-dicarboxylate**

**3,5-dicarboxylate**

**3,5-dicarboxylate**

142.6, 144.6, 161.0, 167.1.

**diethyl ester**

168.0 (C-4″).

Solid: MP 176–178°C; <sup>1</sup>

Solid: MP 158–160°C; <sup>1</sup>

Solid: MP 160–162°C; <sup>1</sup>

**dicarboxylic acid diethyl ester**

Solid: MP 188–190°C; 1

Solid: MP 150–152°C; <sup>1</sup>

129.2, 142.5, 143.2, 160.0, 162.5, 167.1.

Solid: MP 230–232°C; <sup>1</sup>

Solid: MP 168–170°C; <sup>1</sup>

**4b. Di-tert-butyl 4-(4-methoxyphenyl)-l,4-dihydro-2,6-dimethylpyridine-**

3.86 (s, 3H), 4.81 (s, 1H), 5.51 (brs, 1H), 7.10-7.20 (d, 2H), 7.40-7.50 (d, 2H); 13C NMR (125 MHz, CDCl3) δ 19.8, 30.0, 41.0, 56.0, 81.0, 106.1, 125.6, 127.8, 135.0,

**4c. Di-tert-butyl 4-(4-hydroxy-phenyl)-l,4-dihydro-2,6-dimethylpyridine-**

4.90 (s, 1H), 5.56 (brs, 1H), 6.86-6.90 (d, 2H), 7.10-7.20 (d, 2H), 10.10 (s, 1H); 13C NMR (125 MHz, CDCl3) δ 24.5, 32.8, 45.3, 88.0, 108.4, 128.3, 131.0, 134.2, 134.6,

**4d. Di-tert-butyl − 4-(4-fluorophenyl)-l,4-dihydro-2,6-dimethylpyridine-**

6H), 4.81 (s, 1H), 5.50 (brs, 1H), 6.90-6.96 (d, 2H), 7.15-7.20 (d, 2H); 13C NMR (125 MHz, CDCl3) δ 20.0, 21.3, 38.9, 40.0, 79.8, 106.0, 114.2, 113.7, 125.4, 126.8,

**4e. Di-tert-butyl 4-(4-chlorophenyl)-l,4-dihydro-2,6-dimethylpyridine-**

**4 f. Di-tert-butyl − 4-(4-nitrophenyl)-l,4-dihydro-2,6-dimethylpyridine-**

4.86 (s, 1H), 5.55 (brs, 1H), 7.00–7.10 (d, 2H), 7.15–7.25 (d, 2H); 13C NMR (125 MHz, CDCl3) δ 20.5, 22.4, 38.6, 40.1, 79.6, 107.0, 114.5, 114.6, 126.2, 126.8, 129.6,

**4 g. 2,6-Dimethyl-4-phenyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid** 

2CH3CH2), 2.28 (s, 6H, 2CH3), 4.10 (q, *J* = 6 Hz, 4H, 2CH3CH2), 5.00 (s, 1H, CH), 5.75 (s, 1H, NH), 7.10–7.50 (m, 5H); 13C NMR (CDCl3, 75 MHz): δ **=** 14.20 (C-3″), 19.5 (C-1″), 39.6 (C-4), 59.5 (C-2″), 104.1 (C-3 and C-5), 126.0 (C-4′), 127.8 (C-3′ and C-5′), 130.0 (C-2′ and C-6′), 143.8 (C-2 and C-6), 148.0 (C-1′),

**4 h. 2,6-Dimethyl-4-(4-methoxy-phenyl)-1,4-dihydro-pyridine-3,5-**

2.30 (s, 6H), 3.78 (s, 3H), 4.10 (q, *J* = 6.3 Hz, 4H), 4.95 (s, 1H), 5.60 (s, 1H), 6.80

4.85 (s, 1H), 5.50 (brs, 1H), 6.80-6.85 (d, 2H), 7.00-7.08 (d, 2H); 13C NMR (125 MHz, CDCl3) δ 24.3, 33.4, 45.1, 86.2, 108.8, 128.9, 130.4, 133.5, 134.3, 136.1, 148.6, 151.6, 172.4.

H NMR (500 MHz, CDCl3) δ 1.40 (s, 18H), 2.25 (s, 6H),

H NMR (500 MHz, CDCl3) δ 1.36 (s, 18H), 2.28 (s, 6H),

H NMR (500 MHz, CDCl3) δ 1.43 (s, 18H), 2.30 (s,

U NMR (500 MHz, CDCl3) δ 1.38 (s, 18H), 2.25 (s, 6H),

H NMR (500 MHz, CDCl3) δ 1.38 (s, 18H), 2.30 (s, 6H),

H NMR (CDCl3, 400 MHz): δ 1.20 (t, *J* = 9.7 Hz, 6H,

H NMR (CDCl3, 400 MHz): δ 1.21 (t, *J* = 7.0 Hz, 6H),

**226**

## **4p. 2,6-Dimethyl-4-(4-fluoro-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic acid dimethyl ester.**

Solid: MP 170–172°C; 1H NMR (CDCl3, 400 MHz): δ 2.32 (s, 6H, 2CH3), 3.64 (s, 6H, 2CH3), 4.98 (s, 1H, CH), 5.78 (b, 1H), 7.10 (t, 2H), 7.32 (t, 2H); 13C NMR (CDCl3, 75 MHz): δ 19.5, 40.0, 51.0, 104.1, 114.4, 129.3, 130.0, 144.1, 145.3, 160.5, 162.3, 167.6.

## **4q. 2,6-Dimethyl-4-(4-chloro-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic acid dimethyl ester**

Solid: MP 194–196°C; 1H NMR (CDCl3, 400 MHz): δ 2.30 (s, 6H, 2CH3), 3.66 (s, 6H, 2CH3), 4.95 (s, 1H, CH), 5.76 (b, 1H), 7.15 (m, 2H), 7.36 (m, 2H); 13C NMR (CDCl3, 75 MHz): δ 19.5, 39.6, 51.1, 103.6, 113.8, 128.2, 130.0, 144.4, 146.2, 160.4, 167.8.

## **4r. 2,6-Dimethyl-4-(4-nitro-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic acid dimethyl ester**

Solid: MP 210–212°C; 1H NMR (CDCl3, 400 MHz): δ 3.00 (s, 6H, 2CH3), 3.61 (s, 6H, 2CH3), 5.08 (s, 1H, CH), 5.86 (b, 1H), 7.30 (m, 2H), 7.62 (m, 2H); 13C NMR (CDCl3, 75 MHz): δ 19.7, 40.1, 51.2, 103.2, 114.4, 128.7, 145.0, 146.1, 156.2, 167.6.

## **3. Conclusion**

In conclusion, the present study describes the ZnO-NPs catalyzed synthesis of 1,4-dihydropyridines (**4a**–**r**) under microwave irradiation, giving excellent yields in shorter reaction time as compared to conventional method. All the synthesized compounds were evaluated for DNA photocleavage, SAR and DNA docking studies. DNA cleavage by gel electrophoresis method revealed that compounds (**4b** and **4c**) were found to cleave the DNA completely. The preliminary SAR study revealed that the –OCH3 and –OH substituted compounds, were more favorable for activity, particularly at -*para* position of the phenyl ring. Docking studies indicated that one of the ester moieties of these compounds played a key role in their interactions with the DNA. However, the nature of reactive intermediates involved in the DNA cleavage by the 1,4-dihydropyridines has not been clear. Needless to say, further understanding the mechanism of biological action are still required in order to fully develop these compounds as potent anticancer drugs.

## **Acknowledgements**

We are grateful to Prof. H. S. Bhojya Naik, Department of Industrial chemistry, Kuvempu University, for his suggestions, and CeNSE, Indian Institute of science, Bangalore, for providing all necessary facility to carry-out this result.

**229**

**Author details**

Tangali Ramanaik Ravikumar Naik

provided the original work is properly cited.

Vijayanagara Srikrishna Devaraya University (VSKU), Ballari, Karnataka

© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium,

\*Address all correspondence to: naikravi7@gmail.com

*Therapeutic Significance of 1,4-Dihydropyridine Compounds as Potential Anticancer Agents*

*DOI: http://dx.doi.org/10.5772/intechopen.89860*

*Therapeutic Significance of 1,4-Dihydropyridine Compounds as Potential Anticancer Agents DOI: http://dx.doi.org/10.5772/intechopen.89860*

## **Author details**

*Organic Synthesis - A Nascent Relook*

**acid dimethyl ester.**

**acid dimethyl ester**

**acid dimethyl ester**

compounds as potent anticancer drugs.

**Acknowledgements**

**3. Conclusion**

**4p. 2,6-Dimethyl-4-(4-fluoro-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic** 

Solid: MP 170–172°C; 1H NMR (CDCl3, 400 MHz): δ 2.32 (s, 6H, 2CH3), 3.64 (s, 6H, 2CH3), 4.98 (s, 1H, CH), 5.78 (b, 1H), 7.10 (t, 2H), 7.32 (t, 2H); 13C NMR (CDCl3, 75 MHz): δ 19.5, 40.0, 51.0, 104.1, 114.4, 129.3, 130.0, 144.1, 145.3, 160.5, 162.3, 167.6.

**4q. 2,6-Dimethyl-4-(4-chloro-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic** 

Solid: MP 194–196°C; 1H NMR (CDCl3, 400 MHz): δ 2.30 (s, 6H, 2CH3), 3.66 (s, 6H, 2CH3), 4.95 (s, 1H, CH), 5.76 (b, 1H), 7.15 (m, 2H), 7.36 (m, 2H); 13C NMR (CDCl3, 75 MHz): δ 19.5, 39.6, 51.1, 103.6, 113.8, 128.2, 130.0, 144.4, 146.2, 160.4, 167.8.

**4r. 2,6-Dimethyl-4-(4-nitro-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic** 

Solid: MP 210–212°C; 1H NMR (CDCl3, 400 MHz): δ 3.00 (s, 6H, 2CH3), 3.61 (s, 6H, 2CH3), 5.08 (s, 1H, CH), 5.86 (b, 1H), 7.30 (m, 2H), 7.62 (m, 2H); 13C NMR (CDCl3, 75 MHz): δ 19.7, 40.1, 51.2, 103.2, 114.4, 128.7, 145.0, 146.1, 156.2, 167.6.

In conclusion, the present study describes the ZnO-NPs catalyzed synthesis of 1,4-dihydropyridines (**4a**–**r**) under microwave irradiation, giving excellent yields in shorter reaction time as compared to conventional method. All the synthesized compounds were evaluated for DNA photocleavage, SAR and DNA docking studies. DNA cleavage by gel electrophoresis method revealed that compounds (**4b** and **4c**) were found to cleave the DNA completely. The preliminary SAR study revealed that the –OCH3 and –OH substituted compounds, were more favorable for activity, particularly at -*para* position of the phenyl ring. Docking studies indicated that one of the ester moieties of these compounds played a key role in their interactions with the DNA. However, the nature of reactive intermediates involved in the DNA cleavage by the 1,4-dihydropyridines has not been clear. Needless to say, further understanding the mechanism of biological action are still required in order to fully develop these

We are grateful to Prof. H. S. Bhojya Naik, Department of Industrial chemistry, Kuvempu University, for his suggestions, and CeNSE, Indian Institute of science,

Bangalore, for providing all necessary facility to carry-out this result.

**228**

Tangali Ramanaik Ravikumar Naik Vijayanagara Srikrishna Devaraya University (VSKU), Ballari, Karnataka

\*Address all correspondence to: naikravi7@gmail.com

© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

## **References**

[1] Raman DJ, Yus M. Asymmetric multicomponent reactions (AMCRs): The new frontier. Angewandte Chemie, International Edition. 2005;**44**:1602

[2] Domling A. Recent developments in isocyanide based multicomponent reactions in applied chemistry. Chemical Reviews. 2006;**106**:17

[3] Domling A, Ugi I. Multicomponent Reactions with Isocyanides. Angewandte Chemie, International Edition. 2000;**39**:3168

[4] Zhu J, Bienayme H, editors. Multicomponent Reaction. Weinheim: Wiley-VCH; 2005

[5] Tanaka K, Toda F. Solvent-free organic synthesis. Chemical Reviews. 2000;**100**:1025

[6] Li C-J. Organic reactions in aqueous media with a focus on carbon-carbon bond formations: A decade update. Chemical Reviews. 2005;**105**:3095

[7] Paul S, Bhattacharyya P, Das AR. Onepot synthesis of dihydropyrano[2,3-*c*] chromenes via a three component coupling of aromatic aldehydes, malononitrile, and 3-hydroxycoumarin catalyzed by nano-structured ZnO in water: A green protocol. Tetrahedron Letters. 2011;**52**:4636-4641

[8] Ghosh PP, Das AR. Nano crystalline ZnO: A competent and reusable catalyst for one pot synthesis of novel benzylamino coumarin derivatives in aqueous media. Tetrahedron Letters. 2012;**53**:3140

[9] Bhattacharyya P, Pradhan K, Paul S, Das AR. Nano crystalline ZnO catalyzed one pot multicomponent reaction for an easy access of fully decorated 4*H*-pyran scaffolds and its rearrangement to 2-pyridone nucleus in aqueous media. Tetrahedron Letters. 2012;**53**:4687

[10] Ghosh PP, Pal G, Paul S, Das AR. Design and synthesis of benzylpyrazolyl coumarin derivatives via a fourcomponent reaction in water: Investigation of the weak interactions accumulating in the crystal structure of a signified compound. Green Chemistry. 2012;**14**:2691

[11] Jena A, Vinu R, Shivashankar SA, Giridhar M. Microwave assisted synthesis of nanostructured titanium dioxide with high photocatalytic activity. Industrial and Engineering Chemistry Research. 2010;**49**(20):9636-9643

[12] Sai R, Kulkarni SD, Vinoy KJ, Bhat N, Shivashankar SA. ZnFe2O4: Rapid and sub-100°C synthesis and anneal-tuned magnetic properties. Journal of Materials Chemistry. 2012;**22**:2149-2156

[13] Reddy KH, Reddy VVP, Shankar J, Madhav B, Kumar BSPA, Nageswar YVD. Copper oxide nanoparticles catalyzed synthesis of aryl sulfides via cascade reaction of aryl halides with thiourea. Tetrahedron Letters. 2011;**52**:2679-2682

[14] Cristau H-J, Cellier PP, Spindler J-F, Taillefer M. Highly efficient and mild coppercatalyzed N- and C-arylations with aryl bromides and iodides. Chemistry. 2004;**10**(22):5607-5622

[15] Mittapelly N, Reguri BR, Mukkanti K. Copper oxide nanoparticles-catalyzed direct Nalkylation of amines with alcohols. Der Pharma Chemica. 2011;**3**:180-189

[16] Chassaing S, Kumarraja M, Sido ASS, Pale P, Sommer J. Click chemistry in CuI-zeolites: The Huisgen [3 + 2] cycloaddition. Organic Letters. 2007;**9**:883-886

[17] Hudson R, Feng Y, Varma RS, Moores A. Bare magnetic nanoparticles:

**231**

2006;**45**:4718

*Therapeutic Significance of 1,4-Dihydropyridine Compounds as Potential Anticancer Agents*

nanostructures: Synthesis,

characterization, and applications. Advanced Materials. 2003;**15**:353-389

[27] Comparelli R, Fanizza E, Curri ML, Cozzoli PD, Mascolo G, Agostiano A. UV-induced photocatalytic degradation of azo dyes by organiccapped ZnO nanocrystals immobilized onto substrates. Applied Catalysis B:

Environmental. 2005;**60**:1-11

[28] Moghaddam FM, Saeidian H. Controlled microwave-assisted synthesis of ZnO nanopowder and its catalytic activity for *O*-acylation of alcohol and phenol. Materials Science and Engineering B. 2007;**139**:265-269

[29] Mirjafary Z, Saeidian H, Sadeghi A, Moghaddam FM. ZnO nanoparticles: An efficient nanocatalyst for the synthesis of β-acetamido ketones/esters via a multi-component reaction. Catalysis Communications. 2008;**9**:299-306

[30] Gupta M, Paul S, Gupta R, Loupy A. ZnO: A versatile agent for benzylic oxidations. Tetrahedron Letters. 2005;**46**:4957-4960

[31] Lietti L, Tronconi E, Forzatti P. Surface properties of zno-based catalysts and related mechanistic features of the higher alcohol synthesis by FT-IR spectroscopy and TPSR. Journal of Molecular Catalysis.

[32] Sharghi H, Hosseini M. Solvent-free and one-step beckmann rearrangement of ketones and aldehydes by zinc oxide.

[34] Sarvari MH, Sharghi H. Reactions on a solid surface. A simple, economical

1989;**55**:43-54

Synthesis. 2002:1057

[33] Dhakshinamoorthy A, Visuvamithiran P, Tharmaraj V, Pitchumani K. Clay encapsulated ZnO nanoparticles as efficient catalysts for N-benzylation of amines. Catalysis Communications. 2011;**16**:15-19

*DOI: http://dx.doi.org/10.5772/intechopen.89860*

Sustainable synthesis and applications in catalytic organic transformations. Green Chemistry. 2014;**16**:4493-4505

[18] Meldal M, Tornoe CW. Cu-catalyzed azide-alkyne cycloaddition. Chemical

Reviews. 2008;**108**:2952-3015

[19] Hein JE, Fokin VV. Coppercatalyzed azide-alkyne cycloaddition (CuAAC) and beyond: New reactivity of copper(I) acetylides. Chemical Society

Reviews. 2010;**39**:1302-1315

[21] Zhou Y, He T, Wang Z. Nanoparticles of silver oxide immobilized on different templates: Highly efficient catalyst for threecomponent coupling of aldehydeaminealkyne. ARKIVOC. 2008;**xiii**:80-90

2013;**3**:1732-1734

[20] Jin T, Yan M, Yamamoto Y. Click chemistry of alkyne-azide cycloaddition using nano-structured copper catalysts. ChemCatChem. 2012;**4**:1217-1229

[22] Zhou X, Lu Y, Zhai L-L, Zhao Y, Liu Q, Sun W-Y. Propargylamines formed from three-component coupling reactions catalyzed by silver oxide nanoparticles. RSC Advances.

chemical synthesis and formation kinetics of uniformly sized nanocrystals of metals, oxides, and chalcogenides. Accounts of Chemical Research. 2008;**41**:1696

[24] Hu A, Yee GT, Lin W. Magnetically recoverable chiral catalysts immobilized

asymmetric hydrogenation of aromatic ketones. Journal of the American Chemical Society. 2005;**127**:12486

[25] Kawamura M, Sato K. Magnetically separable phase-transfer catalysts. Chemical Communications.

[26] Xia YN, Yang PD, Sun YG, Wu YY, Mayers B, Gates B, et al. One-dimensional

[23] Kwon SG, Hyeon T. Colloidal

on magnetite nanoparticles for

*Therapeutic Significance of 1,4-Dihydropyridine Compounds as Potential Anticancer Agents DOI: http://dx.doi.org/10.5772/intechopen.89860*

Sustainable synthesis and applications in catalytic organic transformations. Green Chemistry. 2014;**16**:4493-4505

[18] Meldal M, Tornoe CW. Cu-catalyzed azide-alkyne cycloaddition. Chemical Reviews. 2008;**108**:2952-3015

[19] Hein JE, Fokin VV. Coppercatalyzed azide-alkyne cycloaddition (CuAAC) and beyond: New reactivity of copper(I) acetylides. Chemical Society Reviews. 2010;**39**:1302-1315

[20] Jin T, Yan M, Yamamoto Y. Click chemistry of alkyne-azide cycloaddition using nano-structured copper catalysts. ChemCatChem. 2012;**4**:1217-1229

[21] Zhou Y, He T, Wang Z. Nanoparticles of silver oxide immobilized on different templates: Highly efficient catalyst for threecomponent coupling of aldehydeaminealkyne. ARKIVOC. 2008;**xiii**:80-90

[22] Zhou X, Lu Y, Zhai L-L, Zhao Y, Liu Q, Sun W-Y. Propargylamines formed from three-component coupling reactions catalyzed by silver oxide nanoparticles. RSC Advances. 2013;**3**:1732-1734

[23] Kwon SG, Hyeon T. Colloidal chemical synthesis and formation kinetics of uniformly sized nanocrystals of metals, oxides, and chalcogenides. Accounts of Chemical Research. 2008;**41**:1696

[24] Hu A, Yee GT, Lin W. Magnetically recoverable chiral catalysts immobilized on magnetite nanoparticles for asymmetric hydrogenation of aromatic ketones. Journal of the American Chemical Society. 2005;**127**:12486

[25] Kawamura M, Sato K. Magnetically separable phase-transfer catalysts. Chemical Communications. 2006;**45**:4718

[26] Xia YN, Yang PD, Sun YG, Wu YY, Mayers B, Gates B, et al. One-dimensional nanostructures: Synthesis, characterization, and applications. Advanced Materials. 2003;**15**:353-389

[27] Comparelli R, Fanizza E, Curri ML, Cozzoli PD, Mascolo G, Agostiano A. UV-induced photocatalytic degradation of azo dyes by organiccapped ZnO nanocrystals immobilized onto substrates. Applied Catalysis B: Environmental. 2005;**60**:1-11

[28] Moghaddam FM, Saeidian H. Controlled microwave-assisted synthesis of ZnO nanopowder and its catalytic activity for *O*-acylation of alcohol and phenol. Materials Science and Engineering B. 2007;**139**:265-269

[29] Mirjafary Z, Saeidian H, Sadeghi A, Moghaddam FM. ZnO nanoparticles: An efficient nanocatalyst for the synthesis of β-acetamido ketones/esters via a multi-component reaction. Catalysis Communications. 2008;**9**:299-306

[30] Gupta M, Paul S, Gupta R, Loupy A. ZnO: A versatile agent for benzylic oxidations. Tetrahedron Letters. 2005;**46**:4957-4960

[31] Lietti L, Tronconi E, Forzatti P. Surface properties of zno-based catalysts and related mechanistic features of the higher alcohol synthesis by FT-IR spectroscopy and TPSR. Journal of Molecular Catalysis. 1989;**55**:43-54

[32] Sharghi H, Hosseini M. Solvent-free and one-step beckmann rearrangement of ketones and aldehydes by zinc oxide. Synthesis. 2002:1057

[33] Dhakshinamoorthy A, Visuvamithiran P, Tharmaraj V, Pitchumani K. Clay encapsulated ZnO nanoparticles as efficient catalysts for N-benzylation of amines. Catalysis Communications. 2011;**16**:15-19

[34] Sarvari MH, Sharghi H. Reactions on a solid surface. A simple, economical

**230**

2012;**53**:3140

*Organic Synthesis - A Nascent Relook*

[1] Raman DJ, Yus M. Asymmetric multicomponent reactions (AMCRs): The new frontier. Angewandte Chemie, International Edition. 2005;**44**:1602

[10] Ghosh PP, Pal G, Paul S, Das AR. Design and synthesis of benzylpyrazolyl

Investigation of the weak interactions accumulating in the crystal structure of a signified compound. Green Chemistry.

[11] Jena A, Vinu R, Shivashankar SA, Giridhar M. Microwave assisted synthesis of nanostructured titanium dioxide with high

photocatalytic activity. Industrial and Engineering Chemistry Research.

[12] Sai R, Kulkarni SD, Vinoy KJ, Bhat N, Shivashankar SA. ZnFe2O4: Rapid and sub-100°C synthesis and anneal-tuned magnetic properties. Journal of Materials Chemistry.

2010;**49**(20):9636-9643

2012;**22**:2149-2156

[13] Reddy KH, Reddy VVP,

Letters. 2011;**52**:2679-2682

Shankar J, Madhav B, Kumar BSPA, Nageswar YVD. Copper oxide nanoparticles catalyzed synthesis of aryl sulfides via cascade reaction of aryl halides with thiourea. Tetrahedron

[14] Cristau H-J, Cellier PP, Spindler J-F, Taillefer M. Highly efficient and mild coppercatalyzed N- and C-arylations with aryl bromides and iodides. Chemistry. 2004;**10**(22):5607-5622

[15] Mittapelly N, Reguri BR, Mukkanti K. Copper oxide nanoparticles-catalyzed direct Nalkylation of amines with alcohols. Der Pharma Chemica. 2011;**3**:180-189

[16] Chassaing S, Kumarraja M, Sido ASS, Pale P, Sommer J. Click chemistry in CuI-zeolites: The Huisgen [3 + 2] cycloaddition. Organic Letters.

[17] Hudson R, Feng Y, Varma RS, Moores A. Bare magnetic nanoparticles:

2007;**9**:883-886

coumarin derivatives via a fourcomponent reaction in water:

2012;**14**:2691

[2] Domling A. Recent developments in isocyanide based multicomponent reactions in applied chemistry. Chemical Reviews. 2006;**106**:17

[3] Domling A, Ugi I. Multicomponent

Multicomponent Reaction. Weinheim:

[6] Li C-J. Organic reactions in aqueous media with a focus on carbon-carbon bond formations: A decade update. Chemical Reviews. 2005;**105**:3095

[7] Paul S, Bhattacharyya P, Das AR. Onepot synthesis of dihydropyrano[2,3-*c*] chromenes via a three component coupling of aromatic aldehydes, malononitrile, and 3-hydroxycoumarin catalyzed by nano-structured ZnO in water: A green protocol. Tetrahedron

[8] Ghosh PP, Das AR. Nano crystalline ZnO: A competent and reusable catalyst for one pot synthesis of novel benzylamino coumarin derivatives in aqueous media. Tetrahedron Letters.

[9] Bhattacharyya P, Pradhan K, Paul S, Das AR. Nano crystalline ZnO catalyzed one pot multicomponent reaction for an easy access of fully decorated 4*H*-pyran scaffolds and its rearrangement to 2-pyridone nucleus in aqueous media. Tetrahedron Letters. 2012;**53**:4687

Letters. 2011;**52**:4636-4641

Angewandte Chemie, International

Reactions with Isocyanides.

[4] Zhu J, Bienayme H, editors.

[5] Tanaka K, Toda F. Solvent-free organic synthesis. Chemical Reviews.

Edition. 2000;**39**:3168

Wiley-VCH; 2005

2000;**100**:1025

**References**

and efficient Friedel-Crafts acylation reaction over zinc oxide (ZnO) as a new catalyst. The Journal of Organic Chemistry. 2004;**69**:6953

[35] Sarvari MH. ZnO/CH3COCl: A new and highly efficient catalyst for dehydration of aldoximes into nitriles under solvent-free condition. Synthesis. 2005;**5**:787

[36] Sarvari MH. Synthesis of β-aminoalcohols catalyzed by ZnO. Acta Chimica Slovenica. 2008;**55**:440

[37] Kim YJ, Varma RS. Microwave assisted preparation of cyclic ureas from diamines in the presence of ZnO. Tetrahedron Letters. 2004;**45**:7205

[38] Sarvari MH, Sharaghi H. ZnO as a new catalyst for N-formylation of amines under solvent-free conditions. The Journal of Organic Chemistry. 2006;**71**:6652

[39] Zhang M, Wang L, Ji H, Wu B, Zenge X. Cumene liquid oxidation to cumene hydroperoxide over CuO nanoparticle with molecular oxygen under mild condition. Journal of Natural Gas Chemistry. 2007;**16**:393-417

[40] Beydoun D, Amal R, Low G, McEvoy S. Role of nanoparticles in photocatalysis. Journal of Nanoparticle Research. 1999;**1**:439-458

[41] Kassaee MZ, Masrouri H, Movahedi F. ZnO-nanoparticlepromoted synthesis of polyhydroquinoline derivatives via multicomponent Hantzsch reaction. Monatshefte für Chemie. 2010;**141**:317-322

[42] Prasad GK, Ramacharyulu PVRK, Singh B, Batra K, Srivastava AR, Ganesan K, et al. Sun light assisted photocatalytic decontamination of sulfur mustard using ZnO nanoparticles. Journal of Molecular Catalysis A: Chemical. 2011;**349**:55

[43] Evans BE, Rittle KE, Bock MG, Dipardo RM, Freidinger RM, Whitter WL, et al. Methods for drug discovery: Development of potent, selective, orally effective cholecystokinin antagonists. Journal of Medicinal Chemistry. 1998;**31**:2235

[44] Muller G. Medicinal chemistry of target family-directed masterkeys. Drug Discovery Today. 2003;**8**:681

[45] Bocker H, Guengerich FP. Oxidation of 4-aryl- and 4-alkyl-substituted 2,6-dimethyl-3,5-bis(alkoxycarbonyl)-1,4 dihydropyridines by human liver microsomes and immunochemical evidence for the involvement of a form of cytochrome P-450. Journal of Medicinal Chemistry. 1986;**29**(9):1596-1603

[46] Sausins A, Duburs G. Synthesis of 1,4-dihydropyridines by cyclocondensation reactions. Heterocycles. 1988;**27**:269-289

[47] Goldman S, Stoltefuss J. 1,4‐ dihydropyridines: Effects of chirality and conformation on the calcium antagonist and calcium agonist activities. Angewandte Chemie International Edition in English. 1991;**30**:559-1578

[48] Bossert F, Meyer H, Wehinger E. 4‐Aryldihydropyridines, a new class of highly active calcium antagonists. Angewandte Chemie International Edition in English. 1981;**20**:762-769

[49] Bossert F, Vater W. 1,4-dihydropyridines--a basis for developing new drugs. Medicinal Research Reviews. 1989;**9**(3):291-324

[50] Buhler FR, Kiowski W. Calcium antagonists in hypertension. Journal of Hypertension. 1987;**5**(3):S3-S10

[51] Reid JL, Meridith PA, Pasanisi F. Clinical pharmacological

**233**

*Therapeutic Significance of 1,4-Dihydropyridine Compounds as Potential Anticancer Agents*

[60] Hantzsch A. Condensationprodukte

ketoniartigen verbindungen. Bernoulli.

Garcia JLN, Alvarez-Builla J. Synthesis

[64] Ohberg L, Westman J. An efficient and fast procedure for the hantzsch dihydropyridine synthesis under microwave conditions. Synlett. 2001;**2001**(8):1296-1298

[65] Agarwal A, Chauhan PMS. Solid supported synthesis of structurally diverse dihydropyrido[2,3-*d*] pyrimidines using microwave irradiation. Tetrahedron Letters.

[66] Phillips AP. Hantzsch's pyridine synthesis. Journal of the American Chemical Society. 1949;**71**:4003

[67] Anderson GJR, Berkelhammer G. A study of the primary acid reaction on model compounds of reduced diphosphopyridine nucleotide. Journal of the American Chemical Society.

[61] Loev B, Snader KM. Oxidation

dihydropyridines. The Journal of Organic Chemistry. 1965;**30**:1914

aus aldehydammoniak und

1881;**14**:1637-1638

1992:297

2005;**46**:1345

1958;**80**:992

[68] Dolly HS, Chimni SS,

Tetrahedron. 1995;**51**:12775

Kumar S. Acid catalysed enamine induced transformations of

1,3-dimethyl-5-formyluracil. A unique annulation reaction with enaminones.

dealkylation of certain

[62] Alajarin R, Vaquero JJ,

of 1,4-dihydropyridines under microwave irradiation. Synlett.

[63] Khadikar BM, Gaikar VG, Chitnavis AA. Aqueous hydrotrope solution as a safer medium for microwave enhanced Hantzsch dihydropyridine ester synthesis. Tetrahedron Letters. 1995;**36**:8083

*DOI: http://dx.doi.org/10.5772/intechopen.89860*

aspects of calcium antagonists and their therapeutic role in hypertension. Journal of Cardiovascular Pharmacology.

[52] Godfaid T, Miller R, Wibo M. Calcium antagonism and calcium entry blockade. Pharmacological Reviews.

[53] Mannhold R, Jablonka B, Voigdt W, Schoenafinger K, Schravan K. Calciumand calmodulin-antagonism of elnadipine derivatives: Comparative SAR. European

[54] Boer R, Gekeler V. Chemosensitizer in tumor therapy: New compounds promise better efficacy. Drugs of the

[55] Bretzel RG, Bollen CC, Maester E, Federlin KF. Nephroprotective effects of nitrendipine in hypertensive type I and type II diabetic patients. American Journal of Kidney Diseases.

[56] Bretzel RG, Bollen CC, Maester E, Federlin KF. Trombodipine platelet aggregation inhibitor antithrombotic. Drugs of the Future. 1992;**17**:465-468

[57] Sridhar R, Perumal PT. A new protocol to synthesize 1,4-dihydropyridines by using 3,4,5-trifluorobenzeneboronic acid as a catalyst in ionic liquid: Synthesis of novel 4-(3-carboxyl-1*H*-pyrazol-4-yl)- 1,4-dihydropyridines. Tetrahedron.

[58] Heravi MM, Behbahani FK, Oskooie HA, Shoar RH. Catalytic aromatization of Hantzsch 1,4-dihydropyridines by ferric

Letters. 2005;**46**:2775

Letters. 2005;**46**:3179

perchlorate in acetic acid. Tetrahedron

[59] Moseley JD. Alternative esters in the synthesis of ZD0947. Tetrahedron

Journal of Medicinal Chemistry.

Future. 1995;**20**:499-509

1985;**7**:S18-S20

1986;**38**:321-327

1992;**27**:229-235

1993;**21**:54-63

2005;**61**:2465

*Therapeutic Significance of 1,4-Dihydropyridine Compounds as Potential Anticancer Agents DOI: http://dx.doi.org/10.5772/intechopen.89860*

aspects of calcium antagonists and their therapeutic role in hypertension. Journal of Cardiovascular Pharmacology. 1985;**7**:S18-S20

*Organic Synthesis - A Nascent Relook*

Chemistry. 2004;**69**:6953

2005;**5**:787

2006;**71**:6652

and efficient Friedel-Crafts acylation reaction over zinc oxide (ZnO) as a new catalyst. The Journal of Organic

[43] Evans BE, Rittle KE,

Chemistry. 1998;**31**:2235

Discovery Today. 2003;**8**:681

[45] Bocker H, Guengerich FP. Oxidation of 4-aryl- and

1986;**29**(9):1596-1603

1991;**30**:559-1578

[49] Bossert F, Vater W.

1,4-dihydropyridines--a basis for developing new drugs. Medicinal Research Reviews. 1989;**9**(3):291-324

[50] Buhler FR, Kiowski W. Calcium antagonists in hypertension. Journal of

Pasanisi F. Clinical pharmacological

Hypertension. 1987;**5**(3):S3-S10

[51] Reid JL, Meridith PA,

of 1,4-dihydropyridines by cyclocondensation reactions. Heterocycles. 1988;**27**:269-289

[47] Goldman S, Stoltefuss J. 1,4‐ dihydropyridines: Effects of chirality and conformation on the calcium antagonist and calcium agonist activities. Angewandte Chemie International Edition in English.

[48] Bossert F, Meyer H, Wehinger E. 4‐Aryldihydropyridines, a new class of highly active calcium antagonists. Angewandte Chemie International Edition in English. 1981;**20**:762-769

4-alkyl-substituted 2,6-dimethyl-3,5-bis(alkoxycarbonyl)-1,4 dihydropyridines by human liver microsomes and immunochemical evidence for the involvement of a form of cytochrome P-450. Journal of Medicinal Chemistry.

[46] Sausins A, Duburs G. Synthesis

Bock MG, Dipardo RM, Freidinger RM, Whitter WL, et al. Methods for drug discovery: Development of potent, selective, orally effective cholecystokinin

antagonists. Journal of Medicinal

[44] Muller G. Medicinal chemistry of target family-directed masterkeys. Drug

[35] Sarvari MH. ZnO/CH3COCl: A new and highly efficient catalyst for dehydration of aldoximes into nitriles under solvent-free condition. Synthesis.

[36] Sarvari MH. Synthesis of

Chimica Slovenica. 2008;**55**:440

[37] Kim YJ, Varma RS. Microwave assisted preparation of cyclic ureas from diamines in the presence of ZnO. Tetrahedron Letters. 2004;**45**:7205

[38] Sarvari MH, Sharaghi H. ZnO as a new catalyst for N-formylation of amines under solvent-free conditions. The Journal of Organic Chemistry.

[39] Zhang M, Wang L, Ji H, Wu B, Zenge X. Cumene liquid oxidation to cumene hydroperoxide over CuO nanoparticle with molecular oxygen under mild condition. Journal of Natural Gas Chemistry. 2007;**16**:393-417

[40] Beydoun D, Amal R, Low G, McEvoy S. Role of nanoparticles in photocatalysis. Journal of Nanoparticle

Research. 1999;**1**:439-458

promoted synthesis of

2010;**141**:317-322

[41] Kassaee MZ, Masrouri H, Movahedi F. ZnO-nanoparticle-

polyhydroquinoline derivatives via multicomponent Hantzsch reaction. Monatshefte für Chemie.

[42] Prasad GK, Ramacharyulu PVRK, Singh B, Batra K, Srivastava AR, Ganesan K, et al. Sun light assisted photocatalytic decontamination of sulfur mustard using ZnO nanoparticles. Journal of Molecular Catalysis A: Chemical. 2011;**349**:55

β-aminoalcohols catalyzed by ZnO. Acta

**232**

[52] Godfaid T, Miller R, Wibo M. Calcium antagonism and calcium entry blockade. Pharmacological Reviews. 1986;**38**:321-327

[53] Mannhold R, Jablonka B, Voigdt W, Schoenafinger K, Schravan K. Calciumand calmodulin-antagonism of elnadipine derivatives: Comparative SAR. European Journal of Medicinal Chemistry. 1992;**27**:229-235

[54] Boer R, Gekeler V. Chemosensitizer in tumor therapy: New compounds promise better efficacy. Drugs of the Future. 1995;**20**:499-509

[55] Bretzel RG, Bollen CC, Maester E, Federlin KF. Nephroprotective effects of nitrendipine in hypertensive type I and type II diabetic patients. American Journal of Kidney Diseases. 1993;**21**:54-63

[56] Bretzel RG, Bollen CC, Maester E, Federlin KF. Trombodipine platelet aggregation inhibitor antithrombotic. Drugs of the Future. 1992;**17**:465-468

[57] Sridhar R, Perumal PT. A new protocol to synthesize 1,4-dihydropyridines by using 3,4,5-trifluorobenzeneboronic acid as a catalyst in ionic liquid: Synthesis of novel 4-(3-carboxyl-1*H*-pyrazol-4-yl)- 1,4-dihydropyridines. Tetrahedron. 2005;**61**:2465

[58] Heravi MM, Behbahani FK, Oskooie HA, Shoar RH. Catalytic aromatization of Hantzsch 1,4-dihydropyridines by ferric perchlorate in acetic acid. Tetrahedron Letters. 2005;**46**:2775

[59] Moseley JD. Alternative esters in the synthesis of ZD0947. Tetrahedron Letters. 2005;**46**:3179

[60] Hantzsch A. Condensationprodukte aus aldehydammoniak und ketoniartigen verbindungen. Bernoulli. 1881;**14**:1637-1638

[61] Loev B, Snader KM. Oxidation dealkylation of certain dihydropyridines. The Journal of Organic Chemistry. 1965;**30**:1914

[62] Alajarin R, Vaquero JJ, Garcia JLN, Alvarez-Builla J. Synthesis of 1,4-dihydropyridines under microwave irradiation. Synlett. 1992:297

[63] Khadikar BM, Gaikar VG, Chitnavis AA. Aqueous hydrotrope solution as a safer medium for microwave enhanced Hantzsch dihydropyridine ester synthesis. Tetrahedron Letters. 1995;**36**:8083

[64] Ohberg L, Westman J. An efficient and fast procedure for the hantzsch dihydropyridine synthesis under microwave conditions. Synlett. 2001;**2001**(8):1296-1298

[65] Agarwal A, Chauhan PMS. Solid supported synthesis of structurally diverse dihydropyrido[2,3-*d*] pyrimidines using microwave irradiation. Tetrahedron Letters. 2005;**46**:1345

[66] Phillips AP. Hantzsch's pyridine synthesis. Journal of the American Chemical Society. 1949;**71**:4003

[67] Anderson GJR, Berkelhammer G. A study of the primary acid reaction on model compounds of reduced diphosphopyridine nucleotide. Journal of the American Chemical Society. 1958;**80**:992

[68] Dolly HS, Chimni SS, Kumar S. Acid catalysed enamine induced transformations of 1,3-dimethyl-5-formyluracil. A unique annulation reaction with enaminones. Tetrahedron. 1995;**51**:12775

[69] Breitenbucher JG, Figliozzi G. Solidphase synthesis of 4-aryl-1,4 dihydropyridines via the Hantzsch three component condensation. Tetrahedron Letters. 2000;**41**:4311

[70] Kumar A, Maurya RA. Synthesis of polyhydroquinoline derivatives through unsymmetric Hantzsch reaction using organocatalysts. Tetrahedron. 2007;**63**:1946

[71] Wang L-M, Sheng J, Zhang L, Han J-W, Fan Z, Tian H, et al. Facile Yb(OTf)3 promoted one-pot synthesis of polyhydroquinoline derivatives through Hantzsch reaction. Tetrahedron. 2005;**61**:1539

[72] Ravikumar Naik TR, Bhojya Naik HS, Prakash Naik HR, Bindu PJ, Harish BG, Krishna V. Synthesis, DNA binding, docking and photoclevage studies of novel benzo[b][1,8] naphthyridines. Medicinal Chemistry. 2009;**5**(5):411

[73] Bindu PJ, Mahadevan KM, Ravikumar Naik TR. Sm(III)nitratecatalyzed one-pot synthesis of furano[3,2c]-1,2,3,4-tetrahydroquinolines and DNA photocleavage studies. Journal of Molecular Structure. 2012;**1020**:142

[74] Bindu PJ, Mahadevan KM, Satyanarayan ND, Ravikumar Naik TR. Synthesis and DNA cleavage studies of novel quinoline oxime esters. Bioorganic & Medicinal Chemistry Letters. 2012;**22**(2):898

[75] Bindu PJ, Mahadevan KM, Naik TRR, Harish BG. Synthesis, DNA binding, docking and photocleavage studies of 2-chloro-3-quinolinyl-3-phenylpropen-2-ones. Medicinal Chemistry Communications. 2014;**5**:1708

[76] Ravikumar Naik TR, Shivashankar SA. Heterogeneous bimetallic ZnFe2O4 nanopowder catalyzed synthesis of

Hantzsch 1,4-dihydropyridines in water. Tetrahedron Letters. 2016;**57**:4046-4049

[77] Janis RA, Silver PJ, Triggle DJ. Drug action and cellular calcium regulation. Aciv, Advances in Drug Research. 1987;**16**:309

[78] Lavilla R. Recent developments in the chemistry of dihydropyridines. Journal of the Chemical Society, Perkin Transactions 1. 2002:1141

[79] Kappe CO. Biologically active dihydropyrimidones of the Biginellitype–a literature survey. European Journal of Medicinal Chemistry. 2000;**35**:1043

[80] Varache-Lemebge M, Nuhrich A, Zemb V, Devaux G, Vacher P, Vacher AM, et al. Synthesis and activities of a thienyl dihydropyridine series on intracellular calcium in a rat pituitary cell line (GH3/B6). European Journal of Medicinal Chemistry. 1996;**31**:547

[81] Alker D, Campbell SF, Cross PE, Burges RA, Carter AJ, Gardiner DG. Long-acting dihydropyridine calcium antagonists. 4. Synthesis and structureactivity relationships for a series of basic and nonbasic derivatives of 2-[(2-aminoethoxy)methyl]-1,4 dihydropyridine calcium antagonists. Journal of Medicinal Chemistry. 1990;**33**:585

[82] Reddy PR, Rao KS, Satyanarayana B. Synthesis and DNA cleavage properties of ternary Cu(II) complexes containing histamine and amino acids. Tetrahedron Letters. 2006;**47**(41):7311-7315

[83] Reddy DS, Hosamani KM, Devarajegowda HC. Design, synthesis of benzocoumarinpyrimidine hybrids as novel class of antitubercular agents, their DNA cleavage and X-ray studies. European Journal of Medicinal Chemistry. 2015;**101**:705-715

**235**

*Therapeutic Significance of 1,4-Dihydropyridine Compounds as Potential Anticancer Agents*

[91] Taha M, Ismail NH, Khan A, Shah SAA, Anwar A, Halim SA, et al. Synthesis of novel derivatives of oxindole, their urease inhibition and molecular docking studies. Bioorganic & Medicinal Chemistry Letters.

2015;**25**(16):3285-3289

*DOI: http://dx.doi.org/10.5772/intechopen.89860*

Photoactivated stereospecific cleavage of double-helical DNA by cobalt(III) complexes. Journal of the American Chemical Society. 1984;**106**:2466

[85] Sigman DS. Nuclease activity of 1,10-phenanthroline-copper ion. Accounts of Chemical Research.

[86] Liu C, Zhou J, Xu H. Interaction of the copper(II) macrocyclic complexes with DNA studied by fluorescence quenching of ethidium. Journal of Inorganic Biochemistry. 1998;**71**:1-6

[87] Suvarna S, Krishna K, Kaushik SH, Rijesh K, Diwakar L, Reddy GC. Synthesis, anticancer and antioxidant activities of 2,4,5-trimethoxy chalcones and analogues from asaronaldehyde: Structureeactivity relationship. European Journal of Medicinal Chemistry. 2013;**62**:435-442

[88] Sun C, Aspland SE, Ballatore C, Castillo R, Smith AB, Castellino AJ. The design, synthesis, and evaluation of two universal doxorubicin-linkers: Preparation of conjugates that retain topoisomerase II activity. Bioorganic & Medicinal Chemistry Letters.

[89] Zhang Y, Zheng W, Luo Q, Zhao Y, Zhang E, Liu S, et al. Dual-targeting organometallic ruthenium(ii) anticancer complexes bearing EGFRinhibiting 4-anilinoquinazoline ligands. Dalton Transactions.

[90] Tabassum S, Zaki M, Afzal M, Arjmand F. New modulated design and synthesis of quercetin-Cu(II)/ Zn(II)-Sn2(IV) scaffold as anticancer agents: In vitro DNA binding profile, DNA cleavage pathway and Topo-I activity. Dalton Transactions.

1986;**19**:180

2006;**16**:104

2015;**44**:13100-13111

2013;**42**(27):10029

[84] Barton JK, Raphael AL.

*Therapeutic Significance of 1,4-Dihydropyridine Compounds as Potential Anticancer Agents DOI: http://dx.doi.org/10.5772/intechopen.89860*

[84] Barton JK, Raphael AL. Photoactivated stereospecific cleavage of double-helical DNA by cobalt(III) complexes. Journal of the American Chemical Society. 1984;**106**:2466

*Organic Synthesis - A Nascent Relook*

phase synthesis of 4-aryl-1,4-

Letters. 2000;**41**:4311

2007;**63**:1946

2009;**5**(5):411

2012;**22**(2):898

2014;**5**:1708

[69] Breitenbucher JG, Figliozzi G. Solid-

Hantzsch 1,4-dihydropyridines in water. Tetrahedron Letters. 2016;**57**:4046-4049

[77] Janis RA, Silver PJ, Triggle DJ. Drug action and cellular calcium regulation. Aciv, Advances in Drug Research.

[78] Lavilla R. Recent developments in the chemistry of dihydropyridines. Journal of the Chemical Society, Perkin

[79] Kappe CO. Biologically active dihydropyrimidones of the Biginellitype–a literature survey. European Journal of Medicinal Chemistry.

[80] Varache-Lemebge M, Nuhrich A,

[81] Alker D, Campbell SF, Cross PE, Burges RA, Carter AJ, Gardiner DG. Long-acting dihydropyridine calcium antagonists. 4. Synthesis and structureactivity relationships for a series of basic and nonbasic derivatives of 2-[(2-aminoethoxy)methyl]-1,4 dihydropyridine calcium antagonists. Journal of Medicinal Chemistry.

[82] Reddy PR, Rao KS, Satyanarayana B. Synthesis and DNA cleavage properties of ternary Cu(II) complexes containing histamine and amino acids. Tetrahedron

Letters. 2006;**47**(41):7311-7315

[83] Reddy DS, Hosamani KM,

Devarajegowda HC. Design, synthesis of benzocoumarinpyrimidine hybrids as novel class of antitubercular agents, their DNA cleavage and X-ray studies. European Journal of Medicinal Chemistry. 2015;**101**:705-715

Vacher AM, et al. Synthesis and activities of a thienyl dihydropyridine series on intracellular calcium in a rat pituitary cell line (GH3/B6). European Journal of Medicinal Chemistry. 1996;**31**:547

Zemb V, Devaux G, Vacher P,

Transactions 1. 2002:1141

1987;**16**:309

2000;**35**:1043

1990;**33**:585

dihydropyridines via the Hantzsch three component condensation. Tetrahedron

[70] Kumar A, Maurya RA. Synthesis of polyhydroquinoline derivatives through

unsymmetric Hantzsch reaction using organocatalysts. Tetrahedron.

[71] Wang L-M, Sheng J, Zhang L, Han J-W, Fan Z, Tian H, et al. Facile Yb(OTf)3 promoted one-pot synthesis of polyhydroquinoline derivatives through Hantzsch reaction.

Tetrahedron. 2005;**61**:1539

[72] Ravikumar Naik TR, Bhojya Naik HS, Prakash Naik HR, Bindu PJ, Harish BG, Krishna V. Synthesis, DNA binding, docking and photoclevage studies of novel benzo[b][1,8]

[73] Bindu PJ, Mahadevan KM, Ravikumar Naik TR. Sm(III)nitratecatalyzed one-pot synthesis of

[74] Bindu PJ, Mahadevan KM,

& Medicinal Chemistry Letters.

[75] Bindu PJ, Mahadevan KM,

naphthyridines. Medicinal Chemistry.

furano[3,2c]-1,2,3,4-tetrahydroquinolines and DNA photocleavage studies. Journal of Molecular Structure. 2012;**1020**:142

Satyanarayan ND, Ravikumar Naik TR. Synthesis and DNA cleavage studies of novel quinoline oxime esters. Bioorganic

Naik TRR, Harish BG. Synthesis, DNA binding, docking and photocleavage studies of 2-chloro-3-quinolinyl-3-phenylpropen-2-ones. Medicinal Chemistry Communications.

[76] Ravikumar Naik TR, Shivashankar SA. Heterogeneous bimetallic ZnFe2O4 nanopowder catalyzed synthesis of

**234**

[85] Sigman DS. Nuclease activity of 1,10-phenanthroline-copper ion. Accounts of Chemical Research. 1986;**19**:180

[86] Liu C, Zhou J, Xu H. Interaction of the copper(II) macrocyclic complexes with DNA studied by fluorescence quenching of ethidium. Journal of Inorganic Biochemistry. 1998;**71**:1-6

[87] Suvarna S, Krishna K, Kaushik SH, Rijesh K, Diwakar L, Reddy GC. Synthesis, anticancer and antioxidant activities of 2,4,5-trimethoxy chalcones and analogues from asaronaldehyde: Structureeactivity relationship. European Journal of Medicinal Chemistry. 2013;**62**:435-442

[88] Sun C, Aspland SE, Ballatore C, Castillo R, Smith AB, Castellino AJ. The design, synthesis, and evaluation of two universal doxorubicin-linkers: Preparation of conjugates that retain topoisomerase II activity. Bioorganic & Medicinal Chemistry Letters. 2006;**16**:104

[89] Zhang Y, Zheng W, Luo Q, Zhao Y, Zhang E, Liu S, et al. Dual-targeting organometallic ruthenium(ii) anticancer complexes bearing EGFRinhibiting 4-anilinoquinazoline ligands. Dalton Transactions. 2015;**44**:13100-13111

[90] Tabassum S, Zaki M, Afzal M, Arjmand F. New modulated design and synthesis of quercetin-Cu(II)/ Zn(II)-Sn2(IV) scaffold as anticancer agents: In vitro DNA binding profile, DNA cleavage pathway and Topo-I activity. Dalton Transactions. 2013;**42**(27):10029

[91] Taha M, Ismail NH, Khan A, Shah SAA, Anwar A, Halim SA, et al. Synthesis of novel derivatives of oxindole, their urease inhibition and molecular docking studies. Bioorganic & Medicinal Chemistry Letters. 2015;**25**(16):3285-3289

## *Edited by Belakatte Parameshwarappa Nandeshwarappa*

The book 'Organic Synthesis - A Nascent Relook' is a compendium of the recent progress in all aspects of organic chemistry including bioorganic chemistry, organometallic chemistry, asymmetric synthesis, heterocyclic chemistry, natural product chemistry, catalytic, green chemistry and medicinal chemistry, polymer chemistry, as well as analytical methods in organic chemistry. The book presents the latest developments in these fields. The chapters are written by chosen experts who are internationally known for their eminent research contributions. Organic synthesis is the complete chemical synthesis of a target molecule. In this book, special emphasis is given to the synthesis of various bioactive heterocycles. Careful selection of various topics in this book will serve the rightful purpose for the chemistry community and the industrial houses at all levels.

Published in London, UK © 2020 IntechOpen © nespix / iStock

Organic Synthesis - A Nascent Relook

Organic Synthesis

A Nascent Relook

*Edited by* 

*Belakatte Parameshwarappa Nandeshwarappa*